Á¦  ¸ñ :   ¼¿¸®¾Çº´µ¶°¨Äڷγª SIRT1 sp1 nrf2

@@@PCR °Ë»ç¿Í ºñ±³ÇØ (¿¡½ºµð¹ÙÀÌ¿À¼¾¼­)½Å¼ÓÇ׿ø°Ë»ç

ÀÇ ¹Î°¨µµ´Â 17.5%,(µÎ ÁÙ·Î ¶Ñ·ÇÀÌ ³ªÅ¸³ª´Â ¾ç¼º¾ç¼ºÆÇ´ÜÀ²...Áï, À§À½¼ºÀ²82.5%....°ËÃâÀÌ ¾ÈµÇ´Â °æ¿ì°¡ ´õ ¸¹´Ù.) ƯÀ̵µ(À½¼ºÀ½¼ºÆÇ´ÜÀ²100% = À§À½¼ºÀÌ Á¦·Î...Áï, µÎÁÙÀÌ ¾È ³ª¿À¸é ÁøÂ¥ À½¼º...¹Ý´ë·Î µÎÁÙÀÌ ¶Ñ·ÇÀÌ ³ª¿À¸é ÁøÂ¥ ¾ç¼ºÀ̶ó´Â ¶æ) 100%·Î ³ªÅ¸³µ´Ù....¹Î°¨µµ´Â °Ë»çÀÚ Áß ¾ç¼ºÀ» ¾ó¸¶³ª Àß Ã£´ÂÁö¸¦ ³ªÅ¸³»´Â ºñÀ²À̰í, ƯÀ̵µ´Â À½¼º ȯÀÚ¸¦ À½¼ºÀ¸·Î Àß ÆÇÁ¤ÇÏ´ÂÁö¸¦ ÃøÁ¤ÇÏ´Â ºñÀ². ƯÀ̵µ°¡ 100%¸é Äڷγª19°¡ ¾Æ´Ñ »ç¶÷À» À߸ø Áö¸ñÇÒ È®·üÀº °ÅÀÇ ¾øÁö¸¸ ¾ç¼º°ËÃâÀ² 17%·Î ¹Î°¨µµ°¡ ³·Àº °Ô ¹®Á¦... 10¸í ȯÀÚ Áß 8¸íÀ» ³õÄ¡´Â °æ¿ì°¡ »ý±ä´Ù´Â ÀǹÌ.


[°Ë»ö : È®ÁøÈ¯ÀÚ Á¢ÃË]...[°³ÀÎÀÇ¿ø Á÷¿ø Äڷγª ¾ç¼ºÆÇÁ¤]

¿ÜºÎ±â°ü¿ë(¹ýÀÎ,±â°ü_µî)_´ëÀÀ_½Ã³ª¸®¿À_±×¸²ÆÇ(°³·«µµ)_2Â÷.pdf


**[[Á÷¿øÁß COVID19¾ç¼ºÀÚ ¹ß»ýÇÑ °æ¿ì¿¡¼­ ..... ÀÚ°¡°Ý¸®±â°£¾øÀÌ ¹æ¿ª Á¾·áÇÏ´Â Á¶°Ç]]  

---- ÀÚ°¡°Ý¸® ÁøÇà ¾øÀÌ (PCRÀ½¼º1ȸ½Ã) ÀÏ»ó»ýȰ·ÎÀÇ º¹±Í°¡ °¡´ÉÇÑ Á¶°Çµé 4°¡Áö  : 

1> Æò¼Ò Á¾ÀÏ KF94¸¶½ºÅ© Âø¿ë ¹× öÀúÇÑ ¼Õ¾Ä±â/¹®°í¸®³ª ¼ÕÀâÀÌ ¼Òµ¶ µî ¿¹¹æ¼öÄ¢ Áؼö öÀú  

2> ÃÑ ´ë»ó ÀοøÁß Àû¾îµµ 3/4´Â ´Éµ¿Àû ¹é½ÅÁ¢Á¾ 1ȸ ¿Ï·á  

3> ¾ç¼ºÆÇÁ¤ÀÚÀÇ ¹ÐÁ¢Á¢ÃËÀÚ¸¦ Æ÷ÇÔÇÑ, ³ª¸ÓÁö Á÷¿øµé ¸ðµÎ PCR°Ë»ç»ó À½¼º ÆÇÁ¤ 

4> ¹é½Å1ȸÁ¶Â÷µµ (¾î¶°ÇÑ ÀÌÀ¯·ÎµçÁö) ¸ÂÁö ¸øÇÑ Á÷¿øÀÌ ÀÖ´Ù ÇÏ´õ¶óµµ °ÅÁÖ °ø°£ÀÌ ¾ç»óÆÇÁ¤ÀڷκÎÅÍ ¶³¾îÁ® ÀÖ°í Ȱµ¿³»¿ëÀÌ ¼­·Î ´Þ¶ó¼­ ¹ÐÁ¢Á¢ÃË ¹ß»ý °¡´É¼ºÀÌ °ÅÀÇ ¾ø´Â °æ¿ì

-myIVTvc10. VD-se-fe.aa51.pppsam.ala300a.

-Dry AMD !! : tumebrom + ActN-ZnSeVD

--COVID19°¨¿°ÀÇ º´ÀÎ..^IFN-1°¨¼Ò=NOX2»ó½Â/ACE2»ó½Â/nrf2ÀúÇÏ ^TGFbeta»ó½Â/TLR4»ó½Â ^STINGÀå¾Ö(IFN-1Áö¿¬, °ú´Ù»ý»ê)--->> **ACTn-tume/brom-ART-ZnSeD 

When Hepatitis B Virus Meets Interferons - NCBI

>>2020.09.09 ¹Ð°¡·ç ¸ø ¸Ô´Â ‘¼¿¸®¾Çº´’, ´Ù¸¥ ¼ÒÈ­±â Áúȯ°ú È¥µ¿Çϱ⠽¬¿ö

Ưº°ÇÑ ÀÌÀ¯ ¾øÀÌ º¹ºÎ ÆØ¸¸°¨°ú ¼³»ç, º¹ÅëÀ» °Þ´Â´Ù¸é °ú¹Î¼º ´ëÀå ÁõÈıºÀ̳ª ¼ÒÈ­ºÒ·®À̶ó°í »ý°¢Çϱ⠽±´Ù. ÇÏÁö¸¸ ÀÌ´Â ¹Ð¿¡ ÇÔÀ¯µÈ ±Û·çÅÙÀ» ¼·ÃëÇÒ ¼ö ¾ø´Â ‘¼¿¸®¾Çº´’ÀÇ ÇÑ Áõ»óÀÏ ¼ö ÀÖ´Ù.

¼¿¸®¾Çº´Àº ±Û·çÅÙ ¼·Ãë·Î ÀÎÇØ ¼ÒÀå¿¡ ¼Õ»óÀ» ÀÔ´Â À¯ÀüÀû ¼ÒÀÎÀÌ ÀÖ´Â »ç¶÷µé¿¡°Ô ¹ß»ýÇÏ´Â ½É°¢ÇÑ ÀÚ°¡ ¸é¿ª Áúȯ Áß Çϳª´Ù. ¼¿¸®¾Çº´ ȯÀÚµéÀº ¸é¿ª°è°¡ ¹Ð, È£¹Ð, º¸¸®¿¡ Æ÷ÇÔµÈ ±Û·çÅÙ¿¡ ´ëÇÑ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ» º¸À̹ǷΠÆò»ý ±Û·çÅÙÀÌ ¾ø´Â ½Ä»ç¸¦ ÇØ¾ß ÇÑ´Ù.

Áõ»óÀ» ¹æÄ¡ÇÒ °æ¿ì ½Åü °÷°÷¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°°í Èí¼öÀå¾Ö·Î ÀÎÇÑ °ñ´Ù°øÁõ, ÇǺιßÁø, Ä¡¾Æ ¹ý¶ûÁú °áÇÔ, ¼ºÀåÁö¿¬, °üÀýÅë, »çÃá±âÁö¿¬, À¯»ê, ºÒÀÓ µîÀÌ º´¹ßÇÒ ¼ö ÀÖ´Ù.

NIH¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 141¸í Áß 1¸íÀÌ ¼¿¸®¾Çº´À» ¾Î°í Àִµ¥, ´Ù¸¥ ¼ÒÈ­±â ÁúȯÀ¸·Î ¿ÀÀÎÇϰí Áõ»óÀ» ¹æÄ¡ÇÏ´Â °æ¿ìµµ ÀûÁö ¾Ê´Ù. Celiac Disease Foundation¿¡¼­´Â ¾à 250¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¼¿¸®¾Ç º´¿¡ ´ëÇØ Áø´Ü¹ÞÁö ¸øÇϰí ÀÖÀ¸¸ç ÀÌ·Î ÀÎÇÑ ½É°¢ÇÑ °Ç°­ ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù°í ¸»ÇÑ´Ù.

¼¿¸®¾Çº´ÀÌ ¹ÐÀ» ÁÖ½ÄÀ¸·Î ¼·ÃëÇÏ´Â ¼­¾çÀε鿡°Ô ÈçÇÑ ÁúȯÀ̶ó°í »ý°¢Çϱ⠽±Áö¸¸, ÀÌ´Â µ¿¾ç¿¡¼­ ¼¿¸®¾Çº´¿¡ ´ëÇÑ ¿¬±¸°¡ Àû±ØÀûÀ¸·Î ÀÌ·ïÁöÁö ¾Ê¾Ò±â ¶§¹®ÀÌ´Ù. 

ƯÈ÷ ½ÒÀÌ ÁÖ½ÄÀÎ ¹®È­±Ç¿¡¼­´Â ±Û·çÅÙ ¼·Ãë°¡ ºó¹øÇÏÁö ¾Ê°í ±×¸¸Å­ Áõ»óÀÌ µå¹°±â ¶§¹®¿¡ ¿Ã¹Ù¸¥ °Ë»ç¿Í Áø´ÜÀÌ ÀÌ·ç¾îÁö´Â µ¥ ÇѰ谡 ÀÖ´Ù.

¼¿¸®¾Çº´ÀÇ ÁÖµÈ Â¡ÈÄ

- ¼³»ç - º¹ºÎ ÆØ¸¸°¨ - °úµµÇÑ °¡½º - ¸¸¼º ÇÇ·Î - üÁß °¨¼Ò - öºÐ °áÇ̼º ºóÇ÷ - º¯ºñ

- ¿ì¿ïÁõ - ÇǺο°, ½ÀÁø, °Ç¼±, ÇǺΠ¹ßÁø

¼¿¸®¾Çº´ÀÌ ÀÖ´Â »ç¶÷µé ´ëºÎºÐÀº °ú¹Î¼º´ëÀåÁõÈıºÀ̶ó´Â Áø´ÜÀ» ¹Þ°í »ì¾Æ°£´Ù. Áõ»óÀÌ ºñ½ÁÇϱ⠶§¹®Àε¥ Áø´Ü ¿¬·ÉÀÌ ´Ê¾îÁú¼ö·Ï ¶Ç ´Ù¸¥ ÀÚ°¡¸é¿ª ÁúȯÀÌ µ¿¹ÝµÉ ¼ö ÀÖ¾î ºü¸¥ Áø´ÜÀÌ Áß¿äÇÏ´Ù. 

°ú¹Î¼º´ëÀåÁõÈıº¿¡ ´ëÇÑ ¾àÀ» º¹¿ëÇÏ°í ½Ä½À°üÀ» ¹Ù²å´Âµ¥µµ ³ª¾ÆÁöÁö ¾Ê´Â´Ù¸é Áõ»ó¿¡ ´ëÇÑ ÀÚ°¡ Áø´ÜÀ» ÅëÇØ ÀÌ»ó ¿©ºÎ¸¦ È®ÀÎÇϰí ÀÇ·á±â°üÀ» ¹æ¹®ÇØ ±Û·çÅÙÇ×ü °Ë»ç¸¦ ½Ç½ÃÇÏ´Â °ÍÀÌ ±ÇÀåµÈ´Ù. ¶ÇÇÑ, °¡Á· ³» ¼¿¸®¾Çº´ ȯÀÚ°¡ ÀÖ´Â °æ¿ì À¯Àü °¡´É¼ºÀÌ ³ôÀ¸¹Ç·Î Áõ»óÀÌ ¾ø´õ¶óµµ °Ë»ç°¡ ÇÊ¿äÇÏ´Ù.

[[**º£¾Æ¸Æ(Æú¶óÇÁ·¹Â¡Å© 75mg/T...23%zinc+77%L-carnosineų·¹ÀÌÆ®Çü) Á¶½ÄÈÄ, ÃëħÀü..±Þ¸¸¼ºÀ§¿°/À§±Ë¾ç(37.5mgZn)]]

>>¿øÀι̻ó üÁß°¨¼Ò

¾Æ¹«¸® ¸Ô¾îµµ »ìÀÌ ÂîÁö ¾Ê´Â °ÍÀº ¸ðµÎ°¡ Èñ¸ÁÇÏ´Â »çÇ×ÀÌÁö¸¸, ½ÇÁ¦·Î ½Ä»ç·®°ú ºñ±³ÇØ »ìÀÌ ÂîÁö ¾Ê°Å³ª ¿ÀÈ÷·Á ¸ö¹«°Ô°¡ ÁÙ¾îµç´Ù¸é °Ç°­ÀÇ ÀÌ»ó ½ÅÈ£ ÀÏ ¼ö ÀÖ´Ù. ¸ðµç üÁß °¨¼Ò°¡ ½É°¢ÇÑ ÁúȯÀÇ Â¡ÈÄ´Â ¾Æ´ÏÁö¸¸, Ưº°ÇÑ ³ë·ÂÀ» ÇÏÁö ¾Ê¾Ò´Âµ¥µµ 6~12°³¿ù ¾È¿¡ 5% ÀÌ»óÀÇ Ã¼ÁßÀÌ ºüÁ³´Ù¸é ½Åü¿¡¼­ ³ªÅ¸³ª´Â ÀÌ»ó Áõ»óÀº ¾ø´ÂÁö È®ÀÎÇØºÁ¾ß ÇÑ´Ù. ÀÌÀ¯ ¾ø´Â üÁß °¨¼Ò°¡ Áö¼ÓµÈ´Ù¸é ´ÙÀ½°ú °°Àº ÁúȯÀ» ÀǽÉÇØº¼ ¼ö ÀÖ´Ù.

°©»ó¼± ±â´É Ç×ÁøÁõ

½Åü ´ë»ç·®À» Á¶ÀýÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °©»ó¼±¿¡¼­ È£¸£¸ó ºÐºñ°¡ °ú´ÙÇØÁö°Å³ª ±â´ÉÀÌ ºñÁ¤»óÀûÀ¸·Î Ç×ÁøµÈ °æ¿ì¿¡´Â ½Åü ´ë»ç°¡ ÇÊ¿ä ÀÌ»óÀ¸·Î Ȱ¹ßÇØÁ® üÁßÀÌ °¨¼ÒÇÒ ¼ö ÀÖ´Ù. ÀÚÀ²½Å°æ ±â´ÉÀÌ ÈïºÐµÇ¾î ½É¹Ú¼ö°¡ »¡¶óÁö¹Ç·Î ½ÉÀåÁúȯÀÌ Àְųª ³ëÀε鿡°Ô´Â ºÎÁ¤¸ÆÀÌ ¹ß»ýÇÒ ¼ö ÀÖ¾î ÁÖÀÇÇØ¾ß ÇÑ´Ù. ¶ÇÇÑ ¿­ ¹ß»ýÀÌ ¸¹¾ÆÁ® ´õÀ§¸¦ Ÿ¸ç, ½Å°æ°ú¹Î, ºÒ¾ÈÁõ ¹× ¾È±¸µ¹Ãú Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.

¾Ï

´ëºÎºÐÀÇ ¾ÏÀº ÀǽÉÇÒ¸¸ÇÑ ÀüÁ¶Áõ»óÀÌ ¾ø´Ù. ´Ü ¸î Á¾·ùÀÇ ¾ÏÀº üÁß ±Þ°¨À» µ¿¹ÝÇϴµ¥, ´ëÇ¥ÀûÀ¸·Î´Â ÃéÀå¾ÏÀÌ ÀÖ´Ù. ÃéÀå¾ÏÀº üÁß°¨¼Ò¿Í Ȳ´Þ, º¹ºÎ ÅëÁõ µîÀÌ ÁÖµÈ Áõ»óÀ¸·Î °¡Á··ÂÀÌ Àְųª ´ç´¢º´ µî °íÀ§Ç豺¿¡ ÇØ´çÇÏ´Â °æ¿ì ÁÖ±âÀûÀÎ °Ç°­°ËÁøÀ» ÇØ¾ß ÇÑ´Ù. ¹Ì±¹ ¾Ï ÇÐȸ¿¡ µû¸£¸é ÃéÀåÀ» ºñ·ÔÇØ Æó, À§ ¹× ½Äµµ¾Ï¿¡¼­ üÁß °¨¼Ò°¡ ÈçÇÏ°Ô ³ªÅ¸³­´Ù.

´ç´¢º´

´ç´¢º´ÀÌ »ý±â¸é ½Åü°¡ Æ÷µµ´çÀ» ¿¡³ÊÁö·Î »ç¿ëÇÏÁö ¸øÇØ ¼Òº¯À¸·Î ºüÁ®³ª°¡¸ç, ÀÌ·Î ÀÎÇØ °¥Áõ°ú ´Ù´¢¸¦ ¹Ýº¹ÇÏ°Ô µÈ´Ù. ´ç´¢º´ ȯÀÚµéÀº ±ÙÀ° °¨¼Ò¸¦ µ¿¹ÝÇϱ⵵ ÇϹǷΠüÁß °¨¼Ò°¡ ÀϾ ¼ö ÀÖ´Ù.

¼¿¸®¾Çº´

±Û·çÅÙ ¼·Ãë¿¡ ´ëÇÑ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ» º¸ÀÌ´Â ÀÚ°¡¸é¿ªÁúȯÀÎ ¼¿¸®¾Çº´ÀÌ À־ üÁß °¨¼Ò¸¦ °ÞÀ» ¼ö ÀÖ´Ù. ¼¿¸®¾Çº´Àº ¹Ð, È£¹Ð, º¸¸®¿¡ Æ÷ÇÔµÈ ±Û·çÅÙ ¼·Ãë ½Ã ¼ÒÀå¿¡ ¼Õ»óÀ» ÀÔ´Â ÁúȯÀ¸·Î ¼³»ç, º¹ºÎ ÆØ¸¸°¨, ¸¸¼ºÇǷθ¦ µ¿¹ÝÇÏ´Â Áõ»óÀ» °æÇèÇÑ´Ù. ¹æÄ¡ ½Ã ½Åü °÷°÷¿¡ ¿°Áõ ¹ÝÀÀ°ú ÇÔ²² Èí¼öÀå¾Ö¸¦ °ÞÀ» ¼ö ÀÖ´Ù.

¸¸¼º Æó¼â¼º Æó Áúȯ

õ½Ä°ú °°Àº ¸¸¼º ±â°üÁö¿°À» Æ÷ÇÔÇÑ ¸¸¼º Æó¼â¼º Æó Áúȯ(COPD)Àº ÈäºÎ ¾Ð¹Ú°ú ÇÔ²² °æ¹ÌÇÑ È£Èí °ï¶õ, °¡º­¿î ±âħÀÌ ÁÖµÈ Â¡ÈÄ·Î ³ªÅ¸³­´Ù. È£ÈíÀÌ Èûµé¾îÁú¼ö·Ï ½Åü´Â ´õ ¸¹Àº ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ°Ô µÇ¹Ç·Î Áõ»óÀÌ ¾ÇÈ­Çϸé üÁß°¨¼Ò°¡ ºü¸£°Ô ÀϾ ¼ö ÀÖ´Ù. Cleveland Clinic¿¡ µû¸£¸é ¸¸¼º Æó¼â¼º Æó ÁúȯÀÌ ÀÖ´Â »ç¶÷µéÀº È£Èí ½Ã Á¤»óÀκ¸´Ù 10¹è ¸¹Àº ¿¡³ÊÁö°¡ ÇÊ¿äÇÏ´Ù.

==========

>>Á¢ÃË·Â ¹ß¿­(Ãʱâ¹Ì¿­-->Á¡Â÷¾ÇÈ­) È£Èí±âÁõ¼¼ ´ëºÎºÐ ¹ßÇö[°Ç±âħ->ÀÎÈÄÅë/Àü½ÅÅë(¸ö»ì, µÎÅë)->¼ûÂü/°´´ãÁõ°¡ =°­·ÂÀǽÉ] + À§ÀåÁõ¼¼ 1/5¹ßÇö [½Ä¿åÀúÇÏ->±¸¿ª±¸Åä15%->º¹Åë<10%->¼³»ç =°­·ÂÀǽÉ] :: È£Èí±âÁõ»ó(°í¿­, °Ç±âħ, ¼ûÂü) ¾ø´Â È£Èí±â¹«Áõ»óÀÚµµ Àֱ⠶§¹®¿¡  Á¢ÃË·Â+ÀåÁõ»ó¸¸ ÀÖ´Ù¸é ÇÇ¶ó¸Æ½º+ÀÚ°¡°Ý¸®¸¸ ÇØµµ ÁÁÀ» °Í))

====Camostat USE=== GERD¿ë¹ý Àû¿ë¿ë·®ÀÌ¸é ¾ÈÀüÇÒ µí(ÇÏ·ç ÃÑ 2.1gmÀÌÇÏ·Î »ç¿ë½Ã).. 

::: 1Á¤´ç 100mgÀ̹ǷÎ===>[±âÁؿ뷮] 170 mg × 2 daily in a 70‐kg human. ..ÇÏ·ç 2ȸ »ç¿ë..1ȸÃßõ¿ë·® ÃßÁ¤ °è»ê ==> 30kg :: 72mg...40Kg :: 97mg...50kg :: 121mg ...60kg: 145mg  70kg :: 170mg.....80kg :: 194 ....90kg :: 218mg 

========

>>2020.09.24 [À±Èñ¿µÀÇ News English] Äڷγª19¿Í µ¶°¨ÀÇ Áõ»ó Â÷ÀÌ ±¸ºÐ¹ý

Äڷγª19¿Í µ¶°¨ÀÌ µ¿½Ã¿¡ â±ÈÇÏ´Â ½ÖµÕÀÌ ÆÒµ¥¹Í(twin pandemics), ‘Æ®À©µ¥¹Í(twindemic)’ ¿ì·Á°¡ Ä¿Áö°í ÀÖ´Ù. µÎ °¨¿°º´(infectious disease)Àº Áõ»óÀÌ ºñ½ÁÇØ Çò°¥¸±(be confused) ¼öµµ ÀÖ¾î ºÒ¾È°¨À» ´õÇÑ´Ù(aggravate anxiety).

µÑÀ» ±¸ºÐÇÒ ¼ö ÀÖ´Â(tell them apart) ¹æ¹ýÀÌ ÀÖ±â´Â ÇÏ´Ù. ¹Ì±¹ ¿ù½ºÆ®¸®Æ®Àú³Î¿¡ µû¸£¸é, ¸Å¿ì Èí»çÇÑ Áõ»óµé(remarkably similar symptoms)À» º¸À̱â´Â ÇÏÁö¸¸, ³ªÅ¸³ª´Â ¼ø¼­°¡ ¾à°£ ´Ù¸£´Ù(be slightly different).

Äڷγª19´Â °í¿­·Î ½ÃÀ۵ȴÙ(begin with a fever). ÀÌÈÄ ±âħ, ¿åÁö±â·±¸Åä, ¼³»ç ¼ø¼­·Î ÁøÇàµÈ´Ù. ù Áõ»óÀÎ °í¿­Àº ¹Ì¿­·Î ½ÃÀÛÇØ(start as a low-grade fever) ½Ã°£ÀÌ Áö³ª¸é¼­ ¾ÇÈ­µÅ(get worse over time) ¿ÀÇÑÀÌ ´À²¸Áö±âµµ ÇÑ´Ù(have chills).

µÎ ¹øÂ° Áõ»óÀº ±âħ(cough)ÀÌ´Ù. µ¶°¨°ú ´Þ¸® ¸¶¸¥ ±âħÀÎ °æÇâÀÌ ÀÖ´Ù(tend to be dry). À̾ ÀÎÈÄ¿°(sore throat), ¸ö»ì(body ache), µÎÅë(headache) µîÀÌ µÚµû¸£±âµµ ÇÑ´Ù. ´ÙÀ½¿£ ¿åÁö±â(nausea)¿Í ±¸Åä(vomiting)°¡ ³ªÅ¸³ª±âµµ Çϰí, ½Ä¿åºÎÁø(lack of appetite)°ú º¹Åë(abdominal pain) °°Àº ¼ÒÈ­±â °èÅë Áõ»óÀÌ À̾îÁö±âµµ ÇÑ´Ù.

°¡Àå ³ªÁß¿¡´Â ¼³»ç(diarrhea) Áõ»óÀÌ ÀϾ´Ù. ±×¸®°í ¹Ì°¢À̳ª Èİ¢À» ÀÒ¾î¹ö¸®°Ô(lose the sense of taste or smell) µÇ´Âµ¥, ÀÌ·± Áõ»óµéÀº µ¶°¨¿¡¼­´Â Á»Ã³·³ ¹ß»ýÇÏÁö ¾Ê´Â´Ù(be unlikely to occur with the flu).

µ¶°¨ Áõ»ó À¯ÇüÀº Äڷγª19¿Í °ÅÀÇ °°Áö¸¸, ÇÑ °¡Áö Áß¿äÇÑ ¿¹¿Ü(exception)°¡ ÀÖ´Ù. °í¿­°ú ±âħÀ̶ó´Â ù µÎ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ø¼­(order of the first two symptoms to appear)°¡ °Å²Ù·Î´Ù(be reversed). Äڷγª19´Â °í¿­·Î ½ÃÀÛµÇ°í ±âħ<ƯÈ÷ °Ç±âħ> Áõ»óÀÌ µÚ¸¦ Àմµ¥ ºñÇØ µ¶°¨Àº ±âħÀÌ ¸ÕÀú ³ª¿À°í °í¿­ÀÌ ³ªÁß¿¡ ¹ß»ýÇÑ´Ù.

µ¶°¨Àº ±âħ µî Áõ»óÀÌ °¨¿° ÀÌÈÄ(after being infected) 1~4ÀÏ À̳»¿¡ ±ÞÀÛ½º·´°Ô ¹ßÇöÇÏ´Â °Í°ú ´Þ¸® Äڷγª19 Áõ»óÀº °¨¿°µÇ°í 2~14ÀÏÀÌ Áö³ª¼­¾ß ³ªÅ¸³­´Ù. ¶Ç µ¶°¨Àº ÀÎÈÄ¿°°ú µÎÅëÀÌ ±âħ°ú °ÅÀÇ °°Àº ½Ã±â¿¡ ³ªÅ¸³ª´Âµ¥(come on about the same time), Äڷγª19¿¡¼± ÀÌ·± Áõ»óµéÀÌ °ÅÀÇ ÀϾÁö ¾Ê´Â´Ù. Ä๰(runny nose)À̳ª ÄÚ¸·Èû(nasal congestion), Àçä±â(sneezing) Çö»óÀÌ »ý±ä´Ù¸é À̰͵µ Äڷγª19°¡ ¾Æ´Ï¶ó µ¶°¨¿¡ °É¸°(come down with the influenza) Áõ»óÀ̶ó°í ÆÇ´ÜÇÏ¸é µÈ´Ù.

ÇÑ °¡Áö ºÐ¸íÇÑ °ÍÀº ¸¶½ºÅ©¸¦ ¾²°í(wear a mask), »çȸÀû °Å¸® µÎ±â¸¦ ÁؼöÇϸç(keep your social distance) ¼ÕÀ» ÀÚÁÖ ¾ÄÀ¸¸é, 3ÁßÀ¸·Î À̷οòÀ» ÁشٴÂ(provide a triple advantage) »ç½ÇÀÌ´Ù. Äڷγª19 È®»êÀ» ÁÙÀ̰í(reduce Covid-19 spread), µ¶°¨ Àü¿° °¡´É¼ºÀ» ³·Ãâ(cut back the chances of influenza transmission) »Ó ¾Æ´Ï¶ó ÀÏ¹Ý °¨±â À§Çèµµ ¹æÁöÇÒ(ward off the risk of the common cold) ¼ö ÀÖ´Â ‘ÀÏ°Å»ïµæ(ìéËáß²Ôð)’ È¿°ú°¡ ÀÖ´Ù.

[[Áõ»óÁøÇà»óÀÇ ºñ±³]]

##COVID : *1)ùÁõ»óÀº ¹ß¿­: óÀ½ ¹Ì¿­·Î ½ÃÀÛ==>°í¿­/¿ÀÇÑ -->*2) ´ë°³ 2-14Àϰæ, ±âħ(°Ç±âħ)-ÀÎÈÄÅë-¸ö»ì-µÎÅë-->*3)±¸¿ª±¸Åä, ½Ä¿åºÎÁø-º¹Åë, ¼³»ç-->*4)¹Ì°¢/Èİ¢»ó½Ç 

##µ¶°¨ : *1)1-4ÀÏÀ̳» ùÁõ»óÀº ±âħ/°¡·¡ + ÀÎÈÄÅë/µÎÅë +ºñ·ç/ºñ»ö/Àçä±â --->*2)°í¿­/¿ÀÇÑ

[Âü°í ¿µ¹®ÀÚ·á »çÀÌÆ®]

¢Ñ https://www.thehealthy.com/infectious-disease/covid-19-symptoms-vs-flu-symptoms/_cmp=TheHealthy&_ebid=TheHealthy9132020&_mid=368937&ehid=a18d22eb68950e7ad262b00aa03c2e0459c6e8ac

¢Ñ https://www.wsj.com/articles/flu-vs-covid-ways-to-identify-symptoms-and-differences-11600088401

¢Ñ https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm

¢Ñ https://www.businessinsider.com/difference-between-coronavirus-symptoms-flu-allergies-common-cold-chart-2020-9 

¢Ñ https://www.muhealth.org/our-stories/flu-cold-or-covid-19-consider-symptoms

----------

¿µÁöÃßÃâ¹°Åõ¿©½Ã antioxidant status (MDA, GSH, SOD, GPx), biochemical (ALT, AST, glucose, triglycerides, cholesterol, urea), and hematological parameters (red blood cells, white blood cells)¸ðµÎ È£Àü, ¿°Áõ/¹ß¿­ ½Å¼Ó È£Àü[pro‐inflammatory cytokines (NF©§B, TNFα, IL6) ÀúÇÏ+ UCP1, SIRT1 ȸº¹] 

-------------

**·çÅ׿ø°(¶¥Äá¼Ó²®Áú¼ººÐÃßÃâ¹°..¿ø·¡ ¹Ì»ö~¿¬³ë¶û~¿¬ºÐÈ«»öÀÌÁö¸¸ ±¸¿ì¸é °¥»ö)---Sirt1½ÅÈ£Àü´Þ ÃËÁøÈ°¼º, KEAP1-NRF2º¹ÇÕüºÐ¸®»ý¼ºÃËÁø-Nrf2ÇϺÎÀÇ Ç×»êÈ­´Ü¹éÁúµé »ó½Â(Ho-1, NQO1, SOD, GSH)//¿°Áõ¼Õ»ó°æ·Î ¹°Áúµé ÀúÇÏ(ROS, TNF-alpha, p38MAPK, p65NFkB)//Ÿ°Ù¼¼Æ÷ÀÇ ¿°Áõ ÀúÇÏ(p53ÀúÇÏ, Bcl-2»ó½Â, BAXÀúÇÏ)

----dry type age-related macular degeneration(AMD)ÀÇ Ä¡·áÀü¸Á----

AMDÀÇ 10%´Â wet type(Ȳ¹Ý³»·ÎÀÇ ºñÁ¤»óÀû Ç÷°üÁõ½ÄÀÌ Æ¯Â¡--Ç×VEGFÄ¡·áÁ¦ »ç¿ë), ±×¿¡ ¹ÝÇØ..³ª¸ÓÁö90%´Â dry type(ROS¿¡ ÀÇÇÑ ¸Á¸·»ö¼Ò»óÇÇ °á¼ÕÀÌ Æ¯Â¡).....NAC(sulfahydryl±â °ø±Þ¿ø/GSHÀü±¸Ã¼)Åõ¿©½Ã GSH¼Ò¸ð°¡ Ư¡(( + inc.NOX4 p22phox>>NOX2, NOX5))ÀÎ Retinal Pigment Epithelium-lossÇü dryAMD(age-related macular degeneration)ÀÇ ¿¹¹æ ¹× Ä¡·á °¡´É¼ºÁõ´ë!!

-----COVID19 and/or Influenza °¨¿°½Ã 1ÇüÀÎÅÍÆä·Ð Áõ»êÀÚ±ØÁ¦---------

***NOX2(NADPH Oxidase2) inhibitors = type I IFN(¾ËÆÄ, º£Å¸) inducer....[È®Á¤] ¹Ù½ºÆ¼³­¿¥¾Ë(TMZ..¼öÃà·ÂÀúÇÏ+ºÎÁ¤¸Æ µ¿¹Ý+ ´ç´¢º´¼º½É±ÙÁõ>ÇãÇ÷½É±ÙÁõ¿¡ Ưȿ)/¸®Æ÷»ê(Ƽ¿ÁÆ®»ê¿¡ÀÌÄ¡¾Ë) SeZnVD-C-B3   ¾ÈÅä½Ã¾Æ´Ñ(ºí·çº£¸®Æú¸®Æä³î),º£¸£º£¸°/º£Å¸½ÃÅ佺Å×·Ñ ¼³Æ÷¶óÆÇ/Ŀť¹Î Çö󺸳ëÀ̵å(Äõ¼¼Æ¾/ÈÖ¼¼Æ¾, įÆä·Ñ, ¸ð¸°)>>[ÃßÁ¤] Ÿ³ª¹Î(Ginko Biloba), HDMPPA(¹èÃß±èġȰ¼º¼ººÐ¸Þź¿ÃÃßÃâ¹°HDMPPA), ¿¡¸ðµò(´ëȲÃßÃâ¹°), ·¹½ºº£¶óÆ®·Ñ(Àû»ö¿ÍÀÎ), ½Ã³ë¸Þ´Ñ>......IFN-1Áõ»êÀÇ ½ÇÁ¦ ¿¹½Ã :: Æò¼Ò, ½ºÇǷ縮³ª15±×·¥ (¶Ç´Â picocyanobilin,​​PCB100mg ÇÔÀ¯ÇÑ ½ºÇǷ縮³ª ÃßÃâ¹°), Á¦2»óÇØµ¶È¿¼ÒÀ¯µµÁ¦ (¿¹ : Æä·ê»ê500~1000mg, ±×´ë½Å ¸®Æ÷»ê1200~1800mg ¶Ç´Â ¼³Æ÷¶óÆÇ), NAC 600mg, ¼¿·¹´½50-100mcg ¹× ¾Æ¿¬50mg  ±Û·çÄÚ»ç¹Î3gÀÌ»ó ¸ÆÁÖÈ¿¸ðº£Å¸-±Û·çÄ­250~500mg ¾ÈÅä½Ã¾Æ´Ñ(¿¤´õº£¸®ÃßÃâ¹° 600~1500mg)

------------

==anti-pdk1(PDK1¾ïÁ¦Á¦)Àº Ç׳ëÈ­ + ³ëÈ­¼¼Æ÷(±×·Î±â»óÅÂ)ÀÇ Á¤»óÈ­ ¿ªÀü ÅëÇØ ¼¼Æ÷¼ö¸í¿¬Àå À¯µµ==

==Ŀť¹ÎÀº anti-PDK1Ȱ¼º±âÀü ÅëÇØ ÀÛ¿ëÇϰí ÀÖÀ½!!! == 

Æ÷½ºÆÄƼµôÀ̳ë½ÃÅç3-Ű³ªÁ¦(PI3K)/Akt (=PKB, ´Ü¹éÁú Ű³ªÁ¦ B¶ó°íµµ ÇÔ) /¶óÆÄ ¸¶À̽ÅÀÇ Æ÷À¯·ùÇ¥Àû(mTOR)½ÅÈ£ ÃàÀº ½ºÆ®·¹½º ¹ÝÀÀ, ¼¼Æ÷ ¼ºÀå ¹× »ýÁ¸À» Æ÷ÇÔÇÑ ¿©·¯ Áß¿äÇÑ ¼¼Æ÷ ±â´ÉÀÇ Á¶Àý¿¡ Á᫐ ¿ªÇÒÀ» ¼öÇàÁß ... CurcuminÀº ´Ü¹éÁú Æ÷½ºÆÄŸÁ¦ ÀÇÁ¸ ¸ÞÄ¿´ÏÁòÀ» ÅëÇØ Akt / mTOR ½ÅÈ£ Àü´ÞÀ» ¾ïÁ¦ÇÔ..., Á» ´õ ¼¼¹ÐÇÏ°Ô ±â¼úÇÑ´Ù¸é, curcumin¿¡ ÀÇÇÑ Akt / mTOR ½ÅÈ£Àü´ÞÀÇ ¾ïÁ¦´Â Ä®¸®Ä𸰠A- ¹Î°¨¼º ´Ü¹éÁú Æ÷½ºÆÄŸÁ¦ ÀÇÁ¸Àû Å»ÀλêÈ­·ÎºÎÅÍ ¹ß»ýÇÑ´Ù´Â °ÍÀÌ ÀÔÁõµÇ¾úÀ½!!!....°á·ÐÀûÀ¸·Î °íÂûÇØ º¸¸é..phosphotidylinositol-dependent kinase-1 (PDK1) ¹× Akt´Â ¼¼Æ÷¸·¿¡ ÇÔ²² µ¿¿ø, ¹ßÇöµÇ°í Akt´Â PDK1 ¹× PDK2 (¾Æ¸¶µµ mTOR º¹ÇÕü 2)¿¡ ÀÇÇØ Thr308 ¹× Ser473 ÀܱâºÎÀ§¿¡¼­ °¢°¢ ÀλêÈ­°¡ ÀϾ°Ô µÈ´Ù ( 2 , 3). ÀλêÈ­¸¦ °ÅÃÄ È°¼ºÈ­ µÈ Akt´Â ±Û¸®ÄÚ°Õ ½Å¼¼Å¸Á¦ Ű³ªÁ¦3 (GSK3), Forkhead°è¿­ Àü»çÀÎÀÚ ¹× mTOR ( 4 )¸¦ Æ÷ÇÔÇÑ °ú´ÙÇÑ ±âÁúÀ» ÀλêÈ­ ¹× Á¶ÀýÇϰí ÀÖ´Â ¹Ý¸é 10 ¹ø ¿°»öü (PTEN)¿¡¼­ °á½ÇµÈ Æ÷½ºÆÄŸÁ¦¿Í ÅٽŻóµ¿Ã¼´Â PIP2¿Í PIP3¸¦ Å» ÀλêÈ­ÇÏ¿© PI3K Ȱ¼ºÀ» ¹æÇØÇÔÀÌ È®ÀεǾú´Ù ( 5 ). =Ŀť¹ÎÀº anti-PDK1Ȱ¼º±âÀü ÅëÇØ ÀÛ¿ëÇϰí ÀÖÀ½!!! 

---------

[SIRT1ÀÇ ÀÌÁßÀÛ¿ë...½ÇÇè½Ç»ó ³»Àμº±âÀüTh17=IL-17AȰ¼ºÁõ°¡..¿ÜºÎsirt1Ȱ¼ºÁ¦Åõ¿©½Ã´ÂTh17¾ïÁ¦] SIRT1activators :: ÀºÇàÀÙÃßÃâ¹°(GBE.Ÿ³ª¹Î) ¾ÈÅä½Ã¾Æ´Ñ/·çÅ×ÀÎ/Á¦¾Æ»êÄ£/¾Æ½ºÅ¸»êÄ£ ·¹½ºº£¶óÆ®·Ñ/Æ÷µµ¾¾ÃßÃâ¹°(GSE. vitis vinisfera.¿£Å×·Ð), Àλï/¸¶Ä«-°¨ÃÊ-¿À¹ÌÀÚ-¿µÁöÃßÃâ¹°. ½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG, Ŀť¹Î, ÆÄÀÌÆä¸°, ¸ÞÆ®Æ÷¸£¹Î. Äõ¼¼Æ¾/ÈÖ¼¼Æ¾. º£Å¸½ÃÅ佺Å×·Ñ º£¸£º£¸°(¸ÅÈ­³ª¹«ÃßÃâ¹°)/·çÅ׿ø°(¶¥Äá²®ÁúÃßÃâ¹°). º£Å¸±Û·çÄ­. CoQ10. MSM. ºñŸ¹Î B3( ´Ï¾Æ½Å+´Ï¾Æ½Å¾Æ¹Ìµå).ºñŸ¹ÎD. DHEA+PREG, ÀÎÅÍÆä·Ð-º£Å¸ NAC(DCMP-dryAMD-µà¼¾Çü±ÙÀÌ¿µ¾çÁõ-COPD:ÇÁ¸®¾ÆÆ¿)//¸ÞÆ®Æ÷¸£¹Î(±Û¶óºñ½º¼­¹æ) -->SIRT1Ȱ¼º==>KEAP1-Nrf2Ȱ¼º ¹× ÇϺÎÇ×»êÈ­´Ü¹éÁúÀ¯µµ + Th17a(=IL-17AȰ¼º : ¼±Ãµ¸é¿ªÀÇ °¨¿°º¸È£ÀÛ¿ë ÀûÁ¤¼º Áõ´ë....SIRT1 activator´Â STAT3 deacetylationÀ» ÅëÇØ Th17ÀÇ ¿À¹ö½´ÆÃÀ» ¹«µð°Ô ÇÏ¿© ¼±Ãµ¸é¿ª+ÈÄõ¸é¿ª¹ÝÀÀÀÇ ÀûÁ¤¼ºÀ» À¯Áö½ÃÅ´)

[NRF2activators] nrf2 »ó½Â, IFN1ÀúÇÏ, NFkB ÀúÇÏÇö»óÀÌ Æ¯Â¡::½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG, Ŀť¹Î ÆÄÀÌÆä¸°(ÈæÈÄÃßÃßÃâ¹°) ºê·Î¸á¸°(ÆÄÀξÖÇÃÃßÃâ¹°), È£³ëŰ¿Ã(¸ñ·ÃÃßÃâ¹°) Ȳ±â(astragalus) HCQ. SAMe+Zn, ALA

--------------------------------------------------------------------

**SP1, specificity protein: DNA¿¡ ÀÛ¿ëÇÏ´Â Àü»çÀÎÀڷμ­ stress-induced NOA(non-oncogenic addiction)¿¡ ¼ÓÇÔ....³ªÀ̵é¸é¼­ ¹ßÇöÀº °¨¼ÒÇÏ´Â °æÇâ.....ÇÑÆí, Á¤»ó¼¼Æ÷°¡ ¾Ï¼¼Æ÷·Î º¯ÇüµÉ ¶§ »ó½ÂÁ¶ÀýµÇ¾î , SP1, SP3, SP4´Â DNAÀÇ ¾Ï¼¼Æ÷º¯ÇüÀ» Áß°³ÇÔ......¾Ï¼¼Æ÷¼ºÀå, »ýÁ¸, À̵¿/ħ½À, ¿°Áõ ¹× ¾àÁ¦ ³»¼º°ú Á÷Á¢ °ü·ÃµÊ.(À§´ëÃéÀå¾Ï-À¯¹æÀü¸³¼±Æó¾Ï-½Å°æÁ¾¿¡¼­ ¿¹Èĺҷ®ÀÎÀÚ).... SP1, SP3, SP4´Â ¿ø·¡ ÀüÇüÀûÀÎ ¾ÏÀ¯ÀüÀÚ°¡ ¾Æ´ÏÁö¸¸ ½ºÆ®·¹½º¿¡ ³ëÃâµÈ °á°ú [¿­ ¹× Àú»ê¼ÒÁõ¿¡ ³ëÃâ·Î ÀÎÇÑ ´Ü¹éÁúº¯Çü½Ã heat-shock protein¹ßÇöÀ» Á¶ÀýÇÏ´Â, heat-shock response·Î ÀÎÇØ »ý¼ºµÇ´Â HSF1(heat-shock factor1)µµ ¸¶Âù°¡Áö] »ý¼ºµÇ´Â Non-oncogenic Addiction(NOA: ºñ¾ÏÀ¯ÀüÀںΰ¡ À¯Àüü)·Î¼­, Ä¡·áÁ¦ Ÿ°ÙºÎÀ§·Î ¸Å¿ì Áß¿ä....Áï, ¾î¶² ½ºÆ®·¹½º°¡ ÁÖ¾îÁ³À» ¶§, curcumin, aspirin and metformin µîÀ» »ç¿ëÇϸé SP TFs¾ïÁ¦¸¦ ÅëÇØ ¾Ï¼¼Æ÷Áõ½ÄÀ» ¸·´Â chemopreventionÈ¿°ú¸¦ ¾ò°ÔµÊ.. 

--**NF-κB and IRF pathways: cross-regulation on target genes promoter level...crosstalk between pathways activated by RIG-I(IFN-1¹ÝÀÀÀ¯µµ) and TLR3 receptors(NFkBȰ¼ºÀ¯µµ) in response to pathogens(¹ÙÀÌ·¯½º)...crosstalk diagram of the IRF - NF-κB pathways. ....members of the NF-κB family may directly impact regulation of IRF family, while IRF members impact regulation of NF-κB family rather indirectly, via other transcription factors such as AP-1 and SP1. =¹ÙÀÌ·¯½º°¨¿°Á÷ÈÄ IFN-1ÀÇ ÃʱâÁõ»ê¹ÝÀÀÀÌ Áö¿¬µÇ´Â ÀÌÀ¯.

---**COVID19°¨¿°½Ã º´ÀαâÀüÀÇ Æ¯Â¡Àº COVID19¿¡ ÀÇÇÑ NRF2 Â÷´Ü/ACE2 Áõ°¡, Ãʱâ IFN-I ÀúÇÏ/TGF-1beta Áõ°¡, TLR4 Áõ°¡, IFN-1ÀÇ Áö¿¬¼º °ú´ÙºÐºñ(STINGÀå¾Ö), Th17¿À¹ö½´ÆÃÀ¸·Î ÀÎÇÑ ARDS/Æó·Å-ÆÐÇ÷Áõ¼º¼ï/´Ù¹ß¼ºÀå±âºÎÀüMODS µîÀÌ Á¦ÀÏ Áß¿ä  ::: Ç׸»¶ó¸®¾ÆÁ¦ÀÎ pyronaridineÀº IFN-1Áõ»êÀÛ¿ëÀÌ Àִµ¥ ¹ÝÇØ, nrf2 Ȱ¼º±â´ÉÀÌ ÀÖ´Â HCQ/CQ/¾Æ¸£Å׹̽ôÑÀÇ ´Üµ¶Åõ¿©´Â ÀϹÝÀûÀÎ nrf2Ȱ¼ºÁ¦µéó·³ IFN 1À» ¿©ÀüÈ÷ °¨¼Ò½ÃŰ±â¿¡ °¨¿°Ãʱ⿡ ¹ÙÀÌ·¯½º¹Ú¸êÀÌ °ï¶õÇÑ ¹®Á¦¸¦ °¡Áö°í ÀÖÀ½ [RA/SLEȯÀÚ¿¡¼­ HCQÀÇ Ä¡·áÈ¿´ÉÀº IFN I°¨¼Ò±âÀüÀ» ¿ªÀÌ¿ëÇØ¼­ °ú´ÙÇ×ÁøµÈ ¸é¿ª½Ã½ºÅÛÀ» ÇÏÇâÁ¶ÀýÇϴµ¥¿¡ ÀÖÀ½ !!], µû¶ó¼­, COVID19°¨¿°Áõ»ó ¹ßÇö½Ã¿¡´Â HCQ/¾Æ¸£Å׹̽ôѿ¡, ¾ÆÁöÆ®·Î¸¶À̽Űú ¾Æ¿¬¿¡ ´õÇÏ¿© Ãʱ⿡ IFN IÀ» Ãß°¡Åõ¿©¸¦ °í·ÁÇϰųª, sirt1Ȱ¼ºÁ¦(Th17À» ¿ÀÈ÷·Á ÇÏÇâÁ¶ÀýÇÔ)À̸鼭 µ¿½Ã¿¡ nrf2Ȱ¼ºÈ¿°ú¸¦ °¡Áö°í ÀÖ´Â Æ®¸®¸ÞŸÁöµò,  ºñŸ¹ÎD, B3, ¾ËÆÄ¸®Æ÷»ê-¾ÈÅä½Ã¾È, ¶Ç´Â Ŀť¹Î-¼³Æ÷¶óÆÇ µîÀÇ NOX2 inhibitor±â´ÉÀ» °¡Áø nrf2 activator>sirt1 activator¸¦ º´¿ëÅõ¿©ÇÏ¿© IFN-1»ó½ÂÀ» À¯µµ + COVID¹Ú¸êÇϸ鼭 µ¿½Ã¿¡ STINGÀå¾Ö ÇØ°á+ Th17¿À¹ö½´ÆÃÀ» Â÷´ÜÇϰí, ÀÌ¿¡ ´õÇÏ¿© NAC·Î TGF-1beta¸¦ Â÷´ÜÇÏ¿© local/systemic fibrosis¿Í ARDSÁøÇàÀ» Â÷´ÜÇØ Áְųª ¾Æ¿¹ ÇÇ¶ó¸Æ½º ¼±ÅÃÀ» °í·ÁÇÒ °Í....-----

^^TGF-1beta Ȱ¼º °æ·Î : viremia-Æó¼¶À¯È­/ARDS À¯¹ß °æ·Î

^^STING Ȱ¼º °æ·Î: cGAS/STING/TBK1/IRF3 innate immunity pathway....LPS-induced TLR4 activation(inc.expression of proinflamm.cytokine such as IRF3, MAPK, NFkB) : ÆÐÇ÷Áõ¼º¼îÅ©/MODSÀ¯¹ß °æ·Î : IRF3´Â ÀÎÅÍÆä·ÐÀÇ Áö¿¬¼º °ú´ÙºÐºñ¿Í ¿¬°áµÊ.

***HCQ and (intranasal) IFR-1 for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances :: [COVID19³ëÃâÀü ¿¹¹æ¸ñÀû »ç¿ë½Ã, ¸»¶ó¸®¾Æ ¿¹¹æ½ºÄÉÁì µû¸¦ °Í...1ÁÖ°£°Ý 1ȸ 400mg½ºÄÉÁì]pre-exposure prophylaxis³ª post-exposure prophylaxis[COVID19ȯÀÚÁ¢ÃËÈÄ ¿¹¹æÀº 5Àϰ£ ¸ÅÀÏ 400mg-¾ÆÁöÆ®·Î¸¶À̽Å-¾Æ¿¬ 3Áß¿ä¹ý..ºñ°­³» IFNÅõ¿© Ãß°¡ °í·Á]¿¡ 80%È¿°ú...
--------------

[[The Role of Natural Products in Targeting Cardiovascular Diseases via Nrf2 Pathway: Novel Molecular Mechanisms and Therapeutic Approaches]]

**NRF2Ȱ¼ºÀ¯µµÁ¦µé(phthalide, Catechin Chalcone DiarylHeptanoid) ÀÛµ¿°æ·Î¿ä¾à

A>Nrf2»ý¼ºÀ¯¸® »ó½ÂÁ¶Àý °æ·Î Ȱ¼º(Á÷Á¢ È¿°ú) : Cul3-Rbx-E2-Ubcomplex=2Keap1=Nrf2 º¹ÇÕü»óŸ¦ p62ÀÚ±ØÇÔÀ¸·Î½á nrf2 inhibitorÀÎ keap1Àº Å»¶ôµÇ°í free Nrf2¸¸ ¼¼Æ÷Áú·Î À¯¸®µÇ¾î ³ª¿È : ÇÙ³»·Î À¯ÀԵǾî sMaf-Nrf2º¹ÇÕü ÀÌ·ç¾î Nrf2Ÿ°ÙÀ¯ÀüÀÚÀÎ ARE geneºÎÀ§¸¦ Ȱ¼º/Àü»ç½ÃÄѼ­ °á±¹ Ç×»êÈ­´Ü¹éÁú ¹× phase II Á¦µ¶È¿¼Ò »ý»êÃËÁø :½ÉÀ庸ȣÀÛ¿ë=Çù½ÉÁõ/½É±Ù°æ»ö/³úÁ¹Áß¿¹¹æÈ¿°ú ¹ßÇö ...nrf2Ȱ¼ºÀÇ Á÷Á¢Àû È¿°ú(¾Æ·¡¿¡ Á¤¸®ÇÔ)

1>Keap1ÀÇÁ¸°æ·Î : *Keap1ÀÇ cysteineº¯Çü *Nrf2/keap1»óÈ£ÀÛ¿ë ÇØÃ¼·Î free Nrf2À¯¸®

2>Keap1ºñÀÇÁ¸°æ·Î :*epigenetic regulation *protein kinases ÀλêÈ­·Î free Nrf2À¯¸®

B>Nrf2¿Í ¿¬°üµÈ ¼¼Æ÷ °æ·Î Ȱ¼º(°£Á¢ È¿°ú) : 1>2>3>°á°ú·Î ½É³úº¸È£ÀÛ¿ë ÃËÁø º¸Á¶

1>ROS ÀúÇÏ + ±Û·çŸġ¿Â ¼öÁØ »ó½ÂÁ¶Àý : *GRD»ó½Â(NADPH¿Í GSSG·Î ºÎÅÍ NADP+, GSH»ý¼ºÁõ°¡) *GPX»ó½Â(GSH¸¦ GSSG·Î º¯È¯Çϸ鼭 °ú»êÈ­¼ö¼Ò¸¦ ¹°·Î ¹Ù²Þ)

2>NFkB¿ÍÀÇ crosstalk.....NFkBÀ¯¸®/Ȱ¼º¾ïÁ¦ = ¿°Áõ»óÅ °³¼± º¸Á¶. : *IKb-NFkBº¹ÇÕüÀÇ ºÐÇØ¸¦ ¾ïÁ¦  == I-kBÀÇ Å»¶ô ¹× I-kB kinase ÀλêÈ­ ¾ïÁ¦¸¦ ÅëÇØ. 

3>foam cell Á¶Àý : ´ë½Ä¼¼Æ÷³»·Î oxLDLÀÌ À¯ÀԵǴ°ÍÀ» ¾ïÁ¦(SR-A, CD36, LOX-1¾ïÁ¦ÅëÇØ) +´ë½Ä¼¼Æ÷·ÎºÎÅÍ ÄÝ·¹½ºÅڷιæÃâÀ» ÃËÁø(ABCA1»ó½Â½ÃÄѼ­ ApoA1»ý»êÀ», ABCG1, SR-B1»ó½Â ÅëÇØ HDL»ý»êÀ» ÃËÁø ---Ç÷°ü¼Õ»ó ¹× µ¿¸Æ°æÈ­º´º¯ ¹ß»ý ¾ïÁ¦ +ÇöóÅ© ÇØ¼ÒÃËÁø

--------------

[[Sirt1/Nrf2 signalling pathway prevents cognitive impairment in diabetic rats through anti‑oxidative stress induced by miRNA‑23b‑3p expression]]

***SIRT1 Ȱ¼ºÀ¯µµÁ¦µéÀº Ç׿°-Ç×»êÈ­-Ç׳ëÈ­-¼¼Æ÷¼ö¸í¿¬Àå/ÀÚ»ì¹æÁö±â´ÉÀ» ³ªÅ¸³»¸ç, SIRT1/nrf2 ½ÅÈ£°æ·Î´Â »êÈ­½ºÆ®·¹½º ÀúÇ×±âÀü ¹× ³ú¼¼Æ÷³» miRNA-23b-3p»ó½ÂÁ¶Àý±âÀüÀ¸·Î ÇнÀ/±â¾ï µî ÀÎÁö±â´É¾ÇÈ­¸¦ ¿¹¹æÇÒ ¼ö Àֱ⿡ Ä¡¸Å/ÆÄŲ½¼º´/Àú»ê¼Ò¼º³ú¼Õ»óÀÇ ¿¹¹æ°ú Ä¡·á¿¡ À¯¸ÁÇÔ... 

[[Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease]] 

ÇÑÆí, SIRT1Àº °£¿¡¼­ Æ÷µµ´ç, ÁöÁú, ÄÝ·¹½ºÅ×·Ñ Ç×»ó¼ºÀ» À¯ÁöÇϸç, ±× Ã˸ÅȰ¼ºÀÌ NAD+ÀÇ ¼¼Æ÷°¡¿ë¼º¿¡ µû¶ó ´Þ¶óÁö´Â Ã˸ÅÀÌÀÚ ´ë»ç¼¾¼­·Î ÀÛ¿ëÇÏ´Â classIII È÷½ºÅæ Å»¾Æ¼¼Æ¿È­È¿¼Ò·Î¼­, SIRT1°ú ¿°Áõ¹ÝÀÀÀÇ ¸¶½ºÅÍÁ¶ÀýÀÚÀÎ NFkB»çÀÌ¿¡´Â »óÈ£±æÇ×see-sawÁ¶Àý°ü°è¿¡ ÀÖÀ½ : NFkBµµ ¹°·Ð SIRT1À» ¾ïÁ¦ÇÒ ¼ö ÀÖÀ¸³ª (±×°á°ú NAFLD¹× °£¿° À¯¹ß) SIRT1Àº NFkbÀÇ p65 ¼­ºêÀ¯´ÖÀ» Å»¾Æ¼¼Æ¿È­ÇÏ¿© ¼¼Æ÷ÇÙÀ¸·ÎºÎÅÍ NFkB¸¦ Á¦°ÅÇϱ⿡ SIRT1Ȱ¼ºÀ¯µµÁ¦µéÀº NAFLD µî Áö¹æ°£ ¹× °£¿° ¹× ¸é¿ª/¿°ÁõÁúȯġ·áÁ¦·Î¼­µµ ¸Å¿ì Áß¿äÇÔ..

[[The systemic role of SIRT1 in exercise mediated adaptation]]

>¼¼Æ÷¿¡³ÊÁö¿ä±¸·®Àº ½Åü ¿îµ¿ Áß¿¡ ½±°Ô º¯°æµÇ¾î NAD+ ÀÇÁ¸¼º ¶óÀ̽е¥¾Æ¼¼Æ¿¶óÁ¦ SIRT1À» Æ÷ÇÔÇÑ ´ë»ç °úÁ¤ÀÇ ´Ü¹éÁú ½ÅÈ£¸¦ ÅëÇØ ÀûÀÀ¹ÝÀÀÀ» ÀÏÀ¸Å´...±ÔÄ¢ÀûÀÎ ¿îµ¿Àº ½Å°æÅðÇ༺Áúȯ ȯÀÚÀÇ ½ÅÀå, °£, ³ú¿¡¼­ SIRT1 ¼öÁØÀ» ȸº¹½ÃŰ´Â Àü½ÅÀû ÀûÀÀÀ» À¯¹ßÇÔÀ¸·Î½á ¼¼Æ÷´ë»ç°úÁ¤À» Á¤»óÈ­Çϰí ÀÌ·¯ÇÑ Áúº´ÀÇ ÁßÁõµµ¸¦ ¾àÈ­½ÃÅ´....°ñ°Ý±Ù¿¡¼­ SIRT1ÀÇ °ú¹ßÇöÀº ±ÙÇÙÀÇ ¼ö¸¦ Áõ°¡½ÃÄÑ ±Ù°ñ°Ý°èÀÇ ºÎ»óÈÄ È¸º¹°úÁ¤À» °³¼±ÇÔ°ú ´õºÒ¾î µ¿È­ÀÛ¿ëÀ» »óÇâÁ¶ÀýÇϰí ÀÌÈ­ÀÛ¿ë °úÁ¤À» ÇÏÇâÁ¶ÀýÇÏ¿© ±ÙÀ° ºñ´ë¿¡ Àû±ØÀûÀ¸·Î °ü¿©ÇÔ

>¾×ƾ¿¡ ¹Ì¿À½Å Á߼⸦ ºÎÂøÇÒ ¶§¸¶´Ù ¸ðµç ºÎÂø°úÁ¤¿¡´Â ATP°¡ ÇÊ¿äÇϱ⠶§¹®¿¡, °í°­µµ¿îµ¿Àº °ñ°Ý±ÙÀ¸·Î ÇÏ¿©±Ý ±×¿¡ ÇÕ´çÇÑ ÃæºÐÇÑ ¾çÀÇ ATP¸¦ »ý»êÇϵµ·Ï ¿ä±¸ÇÏ°Ô µÊ....ÀÌ ATP»ý¼º¿¡´Â ¹ÌÅäÄܵ帮¾Æ ÀüÀÚ Àü´Þ »ç½½¿¡¼­ ÀüÀÚÀÇ À̵¿ ¹× ´Ù¸¥ ¼¼Æ÷Áú ¹× ¹ÌÅäÄܵ帮¾Æ ºÐÀÚµµ ÇʼöÀûÀÓ.. NAD´Â ÀüÀÚ Àü´ÞÀÇ ÇÙ½É ¿ä¼Ò·Î¼­, NADÀÇ È¯¿ø ¹× »êÈ­ (NADH : NAD+ ) ÇüÅÂÀÇ ºñÀ²Àº »êÈ­ ȯ¿ø Ç×»ó¼ºÀ» ¹Ý¿µÇϸç, ÀÌ´Â ¼¼Æ÷ ±¸È¹ ¹× ´ë»ç ¼Óµµ¿¡ µû¶ó ´Þ¶óÁü.  

>LDH(Á¥»ê-Å»¼ö¼ÒÈ¿¼Ò)½Ã½ºÅÛÀº NAD+ : NADH ºñÀ²À» ¹Ý¿µÇϴµ¥,  ¹ÌÅäÄܵ帮¾Æ¿¡¼­ ¼¼Æ÷Áúº¸´Ù ¾à 100 ~ 1000 ¹è ´õ ³ô°í NAD +: NADH ºñÀ²Àº ½ÅÁø ´ë»ç º¯È­¿Í ¹Ýµå½Ã ³ª¶õÈ÷ º´ÇàÇÏ¿© º¯ÇÏÁö´Â ¾ÊÀ½...[ 1 ]. ±×·¯³ª sarcolemma¿¡¼­´Â NAD+ : NADH ºñÀ²ÀÌ Áõ°¡Çϸé SIRT1 mRNA¿Í ´Ü¹éÁú ¼öÁØÀÇ ¹ßÇöÀÌ »ó½ÂµÇ¹Ç·Î[ 2 ]. ½ÅÁø ´ë»ç¸¦ Å©°Ô »ó½Âº¯È­½ÃŰ´Â ½Åü ¿îµ¿ÀÌ NAD+ : NADH ºñÀ²À» º¯°æ½ÃÅ´°ú µ¿½Ã¿¡ ±× °á°ú SIRT1ÀÇ °­·ÂÇÑ À¯µµ¸¦ ¾ß±âÇÑ´Ù´Â °ÍÀº ´ç¿¬Áö»çÀÓ.À̸ç, ÀÌ´Â ³ú-½ÉÀå-°£-½ÅÀå-°ñ°Ý±Ù¿¡ µÎ·ç ¿µÇâÀ» ¹Ìħ

-----[³»Àμº SIRT1 ¹× ¿ÜÀμº SIRT1 activatorÀÇ ±â´Éµé]-----------
Sirtuin 1Àº S. cerevisiae ¿¡ ÀÖ´Â Sir2 À¯ÀüÀÚÀÇ µ¿Á·Ã¼ÀÎ sirtuin °è¿­ ´Ü¹éÁúÀÇ ±¸¼º¿øÀ̸ç sirtuin °è¿­ÀÇ ±¸¼º¿øÀº sirtuin ÇÙ½É µµ¸ÞÀÎÀÌ Æ¯Â¡Àε¥ 4 °³ÀÇ Å¬·¡½º·Î ±×·ìÀ» ³ª´®...Àΰ£ÀÇ sirtuinÀÇ ±â´ÉÀº ¾ÆÁ÷ È®Á¤µÇÁö ¾Ê¾ÒÀ¸³ª È¿¸ð ½Ã¸£ÅõÀÎ ´Ü¹éÁúÀº ÈļºÀ¯ÀüÀû À¯ÀüÀÚ Ä§¹¬À» Á¶Àý Çϰí rDNAÀÇ ÀçÁ¶ÇÕÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ½.....Áö±Ý±îÁöÀÇ ¿¬±¸¿¡ µû¸£¸é Àΰ£ ½Ã¸£ÅõÀÎÀº mono-ADP-ribosylÆ®·£½ºÆÛ¶óÁ¦ Ȱ¼ºÀ» °¡Áø ¼¼Æ÷³» Á¶Àý´Ü¹éÁú·Î ±â´ÉÇÒ ¼ö Àִµ¥, ÀÌ À¯ÀüÀÚ¿¡ ÀÇÇØ ÄÚµùµÈ ´Ü¹éÁúÀº sirtuin °è¿­ÀÇ Å¬·¡½º¿¡ Æ÷ÇÔµÊ
>[Àν¶¸°]Sirtuin 1Àº Àν¶¸°ÀúÇ×¼ºÀÌ ³ôÀº ¼¼Æ÷¿¡¼­´Â ÇÏÇâÁ¶ÀýµÇ¸ç ±× ¹ßÇöÀ» À¯µµÇϸé Àν¶¸°°¨¼ö¼ºÀÌ Áõ°¡ = sirt1ºÐÀÚ°¡ Àν¶¸° °¨¼ö¼º °³¼±°ú °ü·ÃÀÌ ÀÖÀ½À» ½Ã»ç. [9] ¶ÇÇÑ, SIRT1Àº ÇʼöÀûÀÎ ´ë»ç Á¶Àý Àü»ç ÀÎÀÚµéÀÎ PGC1 ¾ËÆÄ / ERR ¾ËÆÄ complexÀÇ ±¸¼º¿ä¼ÒµéÀ» Å»¾Æ¼¼Æ¿È­ ÇÏ°í ±× È°¼º¿¡ ¿µÇâÀ» ¹Ìħ- 
>[p53]Æ÷À¯·ù¿¡¼­ SIRT1Àº p53 ´Ü¹éÁú À» Å»¾Æ¼¼Æ¿È­ÇÏ¿© ºñȰ¼ºÈ­½Ã۸ç autophagy¸¦ ÀÚ±ØÇÔ(=¿­·®Á¦ÇÑÀ¸·Î ÀÎÇÑ ¿µ¾çºÐ¼·ÃëÁ¦Çѽà SIRT1ÀÌ ¼±ÅÃÇÏ´Â ´ë¾ÈÀÓ) ....
>[³ëÈ­]Àΰ£ÀÇ ³ëÈ­´Â chronic, low-grade inflammationÀÌ Æ¯Â¡Àε¥, NF-κB´Â ¿°Áõ°ú °ü·ÃµÈ À¯ÀüÀÚÀÇ ÁÖ¿ä Àü»çÁ¶ÀýÁ¦ÀÓ...sirt1Àº ¶óÀ̽Š310¿¡¼­ NF-κBÀÇ RELA / P65 ¼­ºê À¯´ÖÀ» Å»¾Æ¼¼Æ¿ È­ÇÏ¿© NF-κB-Á¶Àý À¯ÀüÀÚÀÇ ¹ßÇöÀ» ¾ïÁ¦ÇÔÀ¸·Î½á ¿°Áõ-³ëÈ­ÀÇ °³¼± ÅëÇÑ ¼ö¸í¿¬ÀåÀ» À¯µµÇÔ
>[ÀÚ°¡¸é¿ªÁúȯ] ³»ÀμºSIRT1Àº ¼±Ãµ¸é¿ª¿¡ °ü·ÃµÈ TÇïÆÛ17 ¼¼Æ÷¸¦ Ȱ¼ºÈ­ÇÏ´Â ¿ªÇÒÀ» ¼öÇà......¶§·Î, sirt1Ȱ¼ºÀ¯µµ¸ñÀûÀ¸·Î ¸¸µç ÇÕ¼ºÀǾàǰ Åõ¿©´Â ÀÚ°¡¸é¿ªÁúȯÀ» À¯¹ßÇϰųª ¾ÇÈ­½Ãų ¼öµµ ÀÖÀ½...±×·¯³ª, ¿ÜÀμºSIRT1 activator(¸ÞÆ®Æ÷¸£¹Î, ·¹½ºº£¶óÆ®·Ñ, ¸®¸¶±×¸° µî)Åõ¿©½Ã T17¼¼Æ÷ÀÇ ºÐÈ­/Ȱ¼ºÀ» ¾ïÁ¦ÇÔÀÌ È®ÀεǾúÀ½  
>[Áßµ¶] SIRT1Àº D1 À¯Çü µµÆÄ¹Î¼º Áß°£°¡½Ã´º·± ³»ÀÇ HDAC1 ¹× AP-1 ÇÁ·Î¸ðÅÍ º¹ÇÕü¿Í ÇÔ²² Áßµ¶ÀÇ º´Àο¡ ¹ÐÁ¢ÇÏ°Ô °ü·ÃµÇ¾î ÀÖÀ½.
>[»óÈ£ ÀÛ¿ë]Sirtuin 1Àº HEY2 , PGC1-alpha , ERR-alpha , ¹× AIRE ¿Í »óÈ£ ÀÛ¿ëÇϰí ÀÖÀ½.... Mir-132 ¸¶ÀÌÅ©·ÎRNA´Â Sirtuin 1 mRNA¿Í »óÈ£ÀÛ¿ëÇÏ¿© ´Ü¹éÁú¹ßÇöÀ» °¨¼Ò½ÃÅ´À¸·Î½á ºñ¸¸ÀÚÀÇ Àν¶¸°ÀúÇ×À» À¯µµÇÔ 
------------

>>2020.09.24 ¾î¸°ÀÌ¿¡°Õ Èû ¸ø ¾²´Â Äڷγª19... 'ÀÌÀ¯' ¹àÇôÁ³´Ù =Ú¸ ¿¬±¸ÆÀ "¼±Ãµ¼º ¸é¿ª °­ÇÑ ´öºÐ"
¾î¸°ÀÌÀÇ Äڷγª19 Áõ»óÀÌ °æ¹ÌÇÑ ÀÌÀ¯¸¦ ¹àÇô³½ ¿¬±¸ °á°ú°¡ ³ª¿Ô´Ù. º¸Åë ¾î¸°À̵éÀº ¼ºÀκ¸´Ù ¸é¿ª·ÂÀÌ ¾àÇØ °°Àº Áúº´¿¡ °É·Áµµ ´õ À§ÇèÇÑ °æ¿ì°¡ ¸¹´Ù. Áö³­ 2009³â¿¡ À¯ÇàÇß´ø ½ÅÁ¾Ç÷絵 ¼ºÀκ¸´Ù ¾î¸°ÀÌ¿¡°Ô Ä¡¸íÀûÀ̾ú´Ù. ±×·±µ¥, Äڷγª19ÀÇ °æ¿ì ´Ù¼Ò ´Ù¸¥ ¾ç»óÀ» º¸ÀδÙ. ¾î¸°À̵éÀº Äڷγª19¿¡ °É·Áµµ Áõ»óÀÌ °¡º­¿ö ¸¶Ä¡ °¨±âó·³ Áö³ª°¡´Â °æ¿ì°¡ ¸¹Àº °ÍÀÌ´Ù. ÃÖ±Ù ÇмúÁö '»çÀ̾𽺠Áß°³ÀÇÇÐ(Science Translational Medicine)'¿¡´Â ¾î¸°ÀÌÀÇ Äڷγª19 Áõ»óÀÌ °æ¹ÌÇÑ ÀÌÀ¯¸¦ ¹àÇô³½ ¿¬±¸°¡ °ÔÀçµÆ´Ù.
==Äڷγª19 ¼Ò¾Æ ȯÀÚ, '¼±Ãµ¼º ¸é¿ª' ¼öÄ¡ ´õ ³ô´Ù==
¹Ì±¹ ¾Ë¹öÆ® ¾ÆÀν´Å¸ÀÎ Àǰú´ë ¿¬±¸ÆÀÀº ¹Ì±¹ ´º¿å ¸óÅ×ÇÇ¿À·¹ º´¿ø¿¡ Äڷγª19·Î ÀÔ¿øÇÑ ¼ºÀΠȯÀÚ 65¸í°ú ¼Ò¾Æ ȯÀÚ 65¸íÀ» ºñ±³ ºÐ¼®Çß´Ù. ±× °á°ú, ¼ºÀÎÀº ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ¾ÇÈ­µÈ ºñÀ²ÀÌ 37%¿´´ø ¹Ý¸é, ¾ÆÀÌ´Â ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ¾ÇÈ­µÈ ºñÀ²ÀÌ 8%¿¡ ºÒ°úÇß´Ù. »ç¸Á·ü ¶ÇÇÑ ¼ºÀÎÀº 28%, ¼Ò¾Æ´Â 3%·Î Å« Â÷À̸¦ º¸¿´´Ù. ¿¬±¸ÆÀ¿¡ µû¸£¸é ¼Ò¾Æ ȯÀÚ¿¡°Ô¼­´Â '¼±Ãµ¼º ¸é¿ª'°ú °ü·ÃµÈ »çÀÌÅäÄ«ÀÎ ¼öÄ¡(IL-17A=Th17A)°¡ ¼ºÀκ¸´Ù »ó´çÈ÷ ³ô°Ô ³ªÅ¸³µ´Ù. ¿¬±¸ÆÀÀº ÀÌ »çÀÌÅäÄ«ÀÎ ¼öÄ¡°¡ ³ôÀ»¼ö·Ï Äڷγª19ÀÇ ÁÖ¿ä Áõ»ó Áß ÇϳªÀÎ '±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS)'ÀÌ »ý±æ À§ÇèÀÌ ÁÙ¾îµç´Ù°í ºÃ´Ù....(ÇØ¼®)½ÇÀº ¿ÜºÎº´±Õµé¿¡ ´ëÇÑ Th17A ¶Ç´Â IL-17A¼¼Æ÷ÀÇ º¸È£¹ÝÀÀ ±ÕÇüÁ¶ÀýÀÇ ÀûÁ¤¼ºÀÌ °­·ÂÇÏ´Ù°í Ç¥ÇöÇØ¾ß ¸Â´Â ¼³¸íÀÓ...¿ø·¡ Th17¼¼Æ÷´Â ¼±Ãµ¸é¿ª°ú ÈÄõ/ÀûÀÀ¸é¿ªÀÇ ±³Â÷·Î¿¡ À§Ä¡ÇϹǷÎ, Th1(CMI°ü·Ã¼¼Æ÷)/Th17ºñÀ²ÀÌ Áß¿äÇѵ¥ Th17¼¼Æ÷¹ÝÀÀÀÌ ³Ê¹« ¾àÇϸé Á¡¸·ÀÇ °¨¿°¼ºÁúȯ ¹ß»ýÀÌ Àæ°í, ³Ê¹« °­ÇÏ¸é ¿ÀÈ÷·Á »çÀÌÅäÄ«ÀÎÆøÇ³ÀÌ ¾ß±âµÉ ¼ö Àֱ⶧¹®...Th17´Â ¸é¿ª¸Þ¸ð¸®¿Íµµ °ü·ÃµÊ...³»ÀμºSIRT1Àº Th17¼¼Æ÷ÀÇ ¼±Ãµ¸é¿ª ¹× ¸é¿ª±â¾ïÀ» ±ÕÇüÁ¶ÀýÇÔÀ¸·Î½á º¸Á¶ÇÏÁö¸¸, ¿ÜºÎ¿¡¼­ Åõ¿©ÇÑ ¿ÜÀμº SIRT1 activator´Â Th17¼¼Æ÷¸¦ Ȱ¼ºÈ­ Çϱ⵵ ÇÏÁö¸¸ ºÐÈ­¹ÝÀÀÀ» ¹«µð°Ô Çϱ⵵ ÇÔ( Th17¼¼Æ÷ÀÇ ¿À¹ö½´ÆÃÀ¸·Î ÀÎÇÑ »çÀÌÅäÄ«ÀÎÆøÇ³¹ß»ý ¹æÁö °¡´É)..
==°úµµÇÑ 'ÈÄõ¼º ¸é¿ª'ÀÌ Äڷγª°¨¿° Áõ»ó ¾ÇÈ­ÀÇ ÁÖ¹ü==
»ç¶÷ÀÇ ¸é¿ª ÀÛ¿ë¿¡´Â µÎ °¡Áö À¯ÇüÀÌ ÀÖ´Ù. '¼±Ãµ¼º ¸é¿ª'°ú 'ÈÄõ¼º ¸é¿ª(ÀûÀÀ ¸é¿ª)'ÀÌ´Ù. ¼±Ãµ¼º ¸é¿ªÀº ž ¶§ºÎÅÍ ÀÖ´Â °ÍÀ¸·Î, ¸ðµç Á¾·ùÀÇ º´¿øÃ¼°¡ ħÀÔÇßÀ» ¶§ ºü¸£°Ô ¹ÝÀÀÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. ÈÄõ¼º ¸é¿ªÀº ÀÏ´Ü º´¿¡ °É¸° ÈÄ Ç×ü¸¦ Çü¼ºÇØ »ý±â´Â °ÍÀ¸·Î, ƯÁ¤ ¹ÙÀÌ·¯½º³ª ¹Ì»ý¹°À» Ç¥ÀûÀ¸·Î ¹ÝÀÀÇÏ´Â °ÍÀÌ´Ù. ¿¹ÄÁ´ë È«¿ª¿¡ ÇÑ ¹ø °É¸° ÈÄ¿¡´Â ´Ù½Ã °É¸®Áö ¾Ê°Å³ª, ÀΰøÀûÀ¸·Î Ç׿øÀ» ¸¸µé¾î ü³»¿¡ ÁÖ»çÇØ ƯÁ¤ ÁúȯÀ» ¿¹¹æÇÏ´Â µî ¹æ½ÄÀÌ ÈÄõ¼º ¸é¿ª¿¡ ÇØ´çÇÑ´Ù.
Äڷγª19·Î »ç¸ÁÇ߰ųª, ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ½É°¢ÇÑ Áõ»óÀ» º¸ÀΠȯÀÚµéÀº ¹«»çÈ÷ ȸº¹ÇÑ È¯Àڵ麸´Ù 'ÁßÈ­Ç×ü' ¼öÄ¡°¡ ³ô¾Ò´Ù. ÁßÈ­Ç×ü´Â ÈÄõÀû ¸é¿ª ÀÛ¿ëÀ¸·Î ÀÎÇØ »ý±â´Â °ÍÀ¸·Î, ƯÁ¤ ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ÈÄ ±×¿¡ ´ëÀÀÇØ ¸¸µé¾îÁö´Â Ç×ü´Ù. ¿¬±¸ÆÀÀº À̸¦ ±Ù°Å·Î ½ÉÇÑ Äڷγª19 Áõ»óÀÌ Áö³ªÄ£ ÀûÀÀ ¸é¿ªÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ÃßÃøÇß´Ù. ¸é¿ª ¹ÝÀÀÀÌ Á¦´ë·Î ÀÌ·ïÁöÁö ¾Ê¾Æ¼­ Áõ»óÀÌ ½ÉÇØÁø °ÍÀÌ ¾Æ´Ï¶ó, ¿ÀÈ÷·Á °úµµÇÑ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇØ ¿°Áõ ¹ÝÀÀÀÌ ½ÉÇÏ°Ô ³ªÅ¸³µ´Ù´Â Àǹ̴Ù.
=="ÇöÀç °³¹ß Áß ¹é½Å, µµ¿ò ¾È µÉ °¡´É¼º ÀÖ´Ù"==
À̹ø ¿¬±¸ °á°ú´Â ¾ÕÀ¸·Î Äڷγª19 ¹é½ÅÀ» ¸¸µå´Â µ¥µµ À¯ÀǹÌÇÑ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀδÙ. ¿¬±¸¸¦ ÁÖµµÇÑ ºª½Ã ÇØ·Ñµå ¹Ú»ç´Â "ÇöÀç °³¹ß ÁßÀÎ ´ëºÎºÐÀÇ ¹é½Å È帴 ÁßÈ­Ç×ü ¼öÁØÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ´Ù"¸ç "±×·¯³ª ÁßÈ­Ç×ü°¡ dzºÎÇÑ Ç÷ÀåÀº ÀÌ¹Ì Áõ»óÀÌ ³ªÅ¸³­ ¼ºÀο¡°Ô µµ¿òÀÌ µÇÁö ¾ÊÀ» °¡´É¼ºÀÌ ÀÖ´Ù"°í ¸»Çß´Ù. ±×´Â À̾î "Äڷγª19 ¹é½Å¿¡ ¼±Ãµ¼º ¸é¿ªÀ» ³ôÀÌ´Â µî ´Ù¸¥ ¹æ¹ýÀ¸·Î ¸é¿ªÀ» ÃËÁøÇÏ´Â ¹é½ÅÀ» °í·ÁÇØº¼ ¼ö ÀÖÀ» °Í"À̶ó°í µ¡ºÙ¿´´Ù.

--TH17A=IL-17A¸¦ ¸¸µé¾î³»´Â Th¼¼Æ÷±º. °ÅÀÇ ¸ðµç ÀÚ°¡¸é¿ªÁúȯ(SLE, RA, °­Á÷¼ºÃ´Ãß¿° µî)À» À¯¹ß--MSM ¹× sirt1Ȱ¼ºÁ¦¿¡ ¹ÝÀÀÇÔ.

T ÇïÆÛ 17 (Th17) ¼¼Æ÷´Â CD4+ T ¼¼Æ÷ÀÇ Áß¿äÇÑ subset  ::: ½Åü Á¶Á÷À» ħ¹üÇÑ ¼¼Æ÷¿Ü °¨¿°¼º º´¿øÃ¼¸¦ Á¡¸·Ç¥¸é¿¡¼­ Á¦°ÅÇÏ´Â ±âÀü ¼öÇà¿¡ ¸Å¿ì Áß¿ä....¸é¿ª¿¡ À־ Th17 ¼¼Æ÷ÀÇ ±ØÈ÷ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇϰí ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ¸é¿ªÃ¼°è°¡ ÀÌ Th17¼¼Æ÷ À¯ÇüÀÇ »ý»ê ¹× À¯Áö¸¦ ¾î¶² ¹æ½ÄÀ¸·Î Á¶ÀýÇϰí ÀÖ´ÂÁö´Â ¾ÆÁ÷ ¿ÏÀüÈ÷ È®¸³µÈ »óÅ´ ¾Æ´Ô, ƯÈ÷, ÀÌ·¯ÇÑ ¼¼Æ÷ÀÇ °¡¼Ò¼º ¶Ç´Â ´Ù¸¥ CD4+ T¼¼Æ÷ subset·Î Àüȯ ºÐÈ­ÇÏ´Â µ¿Àû ´É·ÂÀº ´ëºÎºÐ Ư¼ºÈ­µÇÁö ¾ÊÀº ä ³²¾Æ ÀÖÀ½..........¸é¿ªÃ¼°è°¡ °É·¯³»Áö ¸øÇÑä ü³»¿¡ ³²°Ô µÇ¸é  IL-17°°Àº ¿°ÁõÇâcytokinesÀÇ Áõ»ê ÅëÇØ ¾Ë·¹¸£±â ¹× ÀÚ°¡¸é¿ªÁúȯÀÌ ¾ß±âµÊ........ÇÑÆí naive T cell¿¡¼­ Th-17cell·ÎÀÇ ºÐÈ­´Â Ȱ¼ºÈ­µÈ Ç׿ø»ý»ê¼¼Æ÷µéÀÌ ºÐºñÇϴ ƯÁ¤ cytokinesµéÀÌ ÀÖ¾î¾ß Çϴµ¥ IL-6(¶Ç´Â IL-21)¹× TGF-beta°¡ ºÐÈ­¿¡ ÀÖ¾î ÀÚ±ØÁ¦·Î ÀÛ¿ëÇϸç, TNF-alpha, IL-1beta, IL_23, sodiumµîÀº ºÐÈ­¸¦ ´õ °­È­½ÃÅ´ Áï, Th17 ¼¼Æ÷ À¯µµ´Â IL-6¿Í TGF β ¶Ç´Â IL-21°ú TGF βÀÇ Á¶ÇÕÀ» ÅëÇØ ¹ß»ý.......ÇÑÆí, VD, retinoic acid, SOCs1m SOCs3µîÀº Th17ºÐÈ­¾ïÁ¦¿¡ °ü¿©.....ºÐÈ­µÈ Th17 ¼¼Æ÷´Â IL-17A, IL-17F, IL-21, IL-22, GM-CSF, IL-9, IL-10 ¹× IFN γ ¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ »çÀÌÅäÄ«ÀεéÀ» »ý»êÇϸç, ÀÌ´Â »çÀÌÅäÄ«ÀΠȯ°æ¿¡ µû¶ó ´Ù¸§.....Th17°èÅëÀ¸·Î Á¤ÀÇµÈ key transcription factors·Î´Â retinoic acid receptor-related orphan receptor(ROR)-gamma(RORgamma) ¹× RORalphaµîÀÌ ÀÖÀ½....³ªÀ̺ê CD4+T ¼¼Æ÷¸¦ Th17 ºÐÈ­·Î À¯µµÇÏ´Â µ¥ °ü·ÃµÈ ´Ù¸¥ Àü»ç ÀÎÀڷδ STAT3, ÀÎÅÍÆä·Ð Á¶Àý ÀÎÀÚ 4 (IRF4), ¾Æ¸± źȭ¼ö¼Ò ¼ö¿ëü (AHR), NOTCH ¹× BATF°¡ ÀÖÀ½.........RA SLE, BA, MS, Psorisis, IBD(CD/UC), type1DM ¸ðµÎ Th17º´ÀαâÀüÀÌ °ü·ÃµÊ.....HCQ´Â Th17°³Ã¼±º °¨¼Ò¸¦ ÅëÇØ IL-6, IL-17 ¹× IL-22ÀÇ »ý¼ºÀ» ¾ïÁ¦ÇÔÀ¸·Î½á SLE Áõ»óÀ» °³¼±...  

....¸»ÃÊÇ÷¾×¿¡¼­ º¼ ¼ö ÀÖ´Â T cell subsetÁß¿¡¼­  ¿°ÁõÇâ subset¿¡´Â Th1 ¹× Th17, Ç׿°Áõsubset¿¡´Â Th2¿Í Treg°¡ ÀÖÀ¸¸ç ¿°Áõ½Ã¿¡´Â ¿°ÁõÇâsubsetÀÇ »ó½Â, Ç׿°ÁõsubsetÀÇ ÀúÇϸ¦ º¼ ¼ö ÀÖÀ¸¸ç Th1°ú Th17»çÀÌ¿¡´Â ¼­·Î moderate negative correlationÀ» º¸ÀÓ...´õºÒ¾î ´ÜÇÙ±¸(Mo)¿Í ÀÚ¿¬»ìÇØ¼¼Æ÷(NK)subsetÀ» Æ÷ÇÔÇÏ´Â innate immunity¿¡¼­ Áõ¿äÇÑ È°µ¿Ã¼µé·Î´Â IL-1beta, IL-6, IFN-gammaµî ¿°ÁõÇâ »çÀÌÅäÄ«ÀεéÀº »ó½Â, ¹Ý¸é¿¡ Ç׿°Áõ»çÀÌÅäÄ«ÀÎÀÎIL-10Àº ÀúÇÏµÊ .....Th17¼¼Æ÷¿Í Treg¼¼Æ÷´Â °øÈ÷ CD4+T cell¿¡ ¼ÓÇÏÁö¸¸ Th17Àº ¿°Áõ¾ÇÈ­, Treg(Treg17)Àº ¿°ÁõÀúÇÏÈ¿°ú¹ßÇöÀ» ¼öÇàÇÔ 

--------[Th17¼¼Æ÷ Á¤¸®]-------
Th17, Th17 cells, T helper 17 cells´Â ¿°Áõ Àü(proinflamm.) µµ¿òT ¼¼Æ÷ Áß¿¡¼­ ÀÎÅÍ·çŲ17 (IL-17)À» »ý¼ºÇÏ´Â Áý´ÜÀ» ¶æÇÑ´Ù. ±×µéÀº Á¶Àý T ¼¼Æ÷¿Í °ü·ÃµÇ¸ç, Th17sÀ» ºÐÈ­½ÃÄÑ ½ÇÁ¦ Á¶Àý T¼¼Æ÷ ºÐÈ­¸¦ ¾ïÁ¦ÇÏ´Â ½ÅÈ£µé°ú °ü·ÃµÈ´Ù. ÇÏÁö¸¸, Th17s´Â ¹ß´Þ»ó¿¡ À־ Th1, Th2¿Í´Â ºÐ¸íÈ÷ ±¸º°µÈ´Ù. Th17¼¼Æ÷´Â Á¡¸· À庮À» À¯ÁöÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Á¡¸· Ç¥¸é¿¡¼­ º´¿øÃ¼¸¦ ¾ø¾Ö´Âµ¥ ±â¿©ÇÑ´Ù. ÇÏÁö¸¸ ÀÌ ¼¼Æ÷±ºÀÇ È°¼º(Áõ½Ä-ºÐÈ­)°ú´Ù ¹× Á¶ÀýÀå¾Ö(=Treg.cell°¨¼Ò)´Â ´Ù¹ß¼º°æÈ­Áõ, RA, SLE, ±â°üÁöõ½Ä, IBD(CD/UC), Á¦1ÇüDM µî ÀÚ°¡¸é¿ª Áúȯ°ú ¿°Áõ¼º Áúº´°ú ¿¬°üµÇ¸ç, ¹Ý¸é¿¡ Á¡¸· Ç¥¸é¿¡¼­ Th17¼¼Æ÷°¡ ÁÙ¾îµå´Â °ÍÀº ¸¸¼º ¿°Áõ°ú ¹Ì»ý¹°ÀÌ ÀüÀ̵Ǵ °Í°úµµ ¿¬°üµÈ´Ù.
==Th17 ¼¼Æ÷ÀÇ ºÐÈ­
º´¿øÃ¼¿Í Á¢ÃËÇÑ ÈÄ È°¼ºÈ­µÈ Ç׿øÁ¦½Ã¼¼Æ÷(APCs, antigen presenting cells)·ÎºÎÅÍ »ý»êµÇ´Â »çÀÌÅäÄ«Àεé, Áï ÇüÁúÀüȯ Áõ½Ä ÀÎÀÚ º£Å¸ (TGF-β), ÀÎÅÍ·çŲ6 (IL-6), ÀÎÅÍ·çŲ21 (IL-21) ÀÎÅÍ·çŲ23 (IL-23) µîÀº naive(¹ÌÁ¢ÃË) T cell·Î ºÎÅÍ Th17ÀÇ ºÐÈ­(Àüȯ)¿¡ ±â¿©ÇÑ´Ù´Â °ÍÀÌ Áã¿Í »ç¶÷¿¡¼­ È®ÀεƴÙ. À̶§ Th17 ¼¼Æ÷ ºÐÈ­ÀÇ Áß¿äÁ¶Àý Ÿ°ÙÀ¸·Î´Â Stat3 (Signal transducer and the activator of transcription 3)°ú RORγ(retinoic acid receptor-related orphan receptors gamma)¿Í RORα µîÀÌ ÀÖ´Ù. Th17¼¼Æ÷´Â ±Ã±ØÀûÀ¸·Î ±×µéÀÇ ºÐÈ­ ÇÁ·Î±×·¥À» ¹Ù²ã¼­ º¸È£ ¼¼Æ÷(¼±Ãµ¸é¿ª °ü·Ã) ¶Ç´Â Àü¿°Áõ¼º(proinflamm.) º´¿ø¼º ¼¼Æ÷°¡ µÇµµ·Ï Çϴµ¥, IL-6°ú TGF-β¿¡ ÀÇÇØ À¯µµµÇ¸ç ¼±Ãµ¸é¿ªÀ» ´ã´çÇÏ´Â(º¸È£ÀÛ¿ëÀ» ÇÏ´Â) ºñº´¿ø¼ºÀÇ Th17¼¼Æ÷´Â µû·Î Treg17 ¼¼Æ÷¶ó µû·Î ÁöĪÇϸç, Àü¿°Áõ¼º(º´¿ø¼º...proinflamm.cytokineºÐºñÀÇ ÁÖ¹ü) Th17¼¼Æ÷´Â IL-23°ú IL-1β¿¡ ÀÇÇØ ÁÖ·Î À¯µµµÈ´Ù. Th17¼¼Æ÷ Àڽſ¡ ÀÇÇØ »ý¼º-ºÐºñµÇ´Â(autocrine) IL-21´Â Th17¼¼Æ÷ÀÇ ¶Ç´Ù¸¥ ºÐÈ­°æ·Î¸¦ ¹ßµ¿½ÃŰ°Ô µÇ¸ç, ÇÑÆí. Th1ÀÇ ÁÖ¿ä ºÐÈ­ÀÎÀÚÀÎ ÀÎÅÍÆä·Ð°¨¸¶(IFNy)¿Í Th2 ºÐÈ­ÀÇ ÁÖ¿ä Ȱ¼ºÀÎÀÚÀÎ IL-4µéÀº ¸ðµÎ Th17ÀÇ ºÐÈ­¸¦ ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
==Th17 ¼¼Æ÷ÀÇ ±â´É
Th17 ¼¼Æ÷´Â º´¿øÃ¼·ÎºÎÅÍ ¸öÀ» º¸È£ÇÏ´Â ÀûÀÀ ¸é¿ª¿¡À־ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ÇÏÁö¸¸, °õÆÎÀ̱տ¡ ´ëÇ×ÇÏ´Â ¸é¿ªÀº ƯÁ¤ºÎÀ§¿¡¸¸ Á¦ÇÑÀûÀ¸·Î ³ªÅ¸³ª¸ç ÇØ·Î¿î È¿°úµéÀÌ °üÂûµÇ¾ú´Ù. ±×µéÀÇ ÁÖ¿ä È¿°ú »çÀÌÅäÄ«ÀÎ(effector cytokines)Àº IL-17A, IL-17F, IL-21°ú IL-22 µîÀÌ´Ù. Th17Àº Á¾¾çÀÇ À§ÃàÀ» ¸Å°³Çϴ°ÍÀÌ Áã¿¡¼­ ³ªÅ¸³µÁö¸¸ ¶ÇÇÑ °áÀå(colon)ÀÇ ¿°Áõ¿¡ ÀÇÇØ ÀڱصǾî Á¾¾çÇü¼ºÀ» ÃËÁøÇÏ´Â °á°ú ¶ÇÇÑ Áã¿¡¼­ ³ªÅ¸³µ´Ù. ´Ù¸¥ µµ¿ò T ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î, Th17 ¼¼Æ÷´Â º´¿øÃ¼¿¡ ¹ÝÀÀÇϴµ¥ ÀÖ¾î B¼¼Æ÷¿Í ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÈ´Ù. Th17¼¼Æ÷´Â CXCL13 ۸ðÄ«ÀÎ(chemokine) ½ÅÈ£Àü´ÞÀ» ÅëÇØ B¼¼Æ÷ º¸°­°ú °ü·ÃµÇ¸ç, Th17 Ȱ¼ºÀº Ç×ü Çü¼ºÀ» µµ¿ï ¼ö ÀÖ´Ù.
==Th17¼¼Æ÷ °ü·Ã Áúº´
Th17¼¼Æ÷ÀÇ Á¶ÀýÀå¾Ö´Â ÀÚ°¡¸é¿ª Áúȯ°ú ¿°Áõ¿¡ °ü·ÃµÈ´Ù. ÀÚ°¡¸é¿ª¼º ÁúȯÀÇ °æ¿ì, Th17¼¼Æ÷ÀÇ °úµµÇÑ È°¼ºÀº ·ù¸¶Æ¼½º °üÀý¿°ÀÇ °æ¿ìó·³ ºÒÇÊ¿äÇÏ°Ô ¸¹Àº ¾çÀÇ ¿°ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. Th17¼¼Æ÷´Â Á¡¸· ¸é¿ªÀ» À¯ÁöÇϴµ¥ ÇÊ¿äÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. HIVÀÇ °æ¿ì¸¦ º¸¸é, Th17¼¼Æ÷°¡ ÁÙ¾îµå´Â°ÍÀÌ ¸¸¼º ¿°Áõ¿¡ ±â¿© ÇÒ ¼öµµ ÀÖ´Ù.
---[SIRT1 activatorÅõ¿©ÀÇ ÀÕÁ¡ Á¤¸®]----------
[[Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation]]
<ÁßÁ¡Á¤¸®>
=SIRT1Ȱ¼ºÁ¦´Â activation impedes Th17 cell ÀÇ STAT3 deacetylation ¹× Rorc promoter°áÇÕ´ÉÀ» ¾ïÁ¦½ÃŰ¸ç ±× °á°ú Th17ºÐÈ­¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á »ýÁã¿¡¼­ Á¾¾ç¼ºÀåÀ» ¾ïÁ¦Çϰí ȯÀÚ¿¡¼­ TRh17 ºóµµ¸¦ °¨¼Ò½ÃÄ×À¸¸ç, SIRT1 activators [¸®¸¶±×¸°, ¸ÞÆ®Æ÷¸£¹Î, ·¹½ºº£¶óÆ®·Ñ]µéÀº ¾ÏȯÀڵ鿡°Ô¼­µµ  IL-17A protumor functionsÀ» Á÷Á¢ ¾ïÁ¦ Ÿ°ÙÆÃÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖÀ½
<¹è°æ>
Sirtuin-1Àº ƯÁ¤´Ü¹éÁúÀÇ Å»¾Æ¼¼Æ¿È­¸¦ ÅëÇØ ´Ù¾çÇÑ ¼¼Æ÷ÀÇ ¿°Áõ°úÁ¤¿¡ À־ °áÁ¤ÀûÀÎ Á¶ÀýÀÚÀÓÀÌ ÀÔÁõµÇ¾úÀ½  
³»Àμº(Basal) SIRT1 Ȱ¼ºÀº (»ýÁã½ÇÇè»ó)Th9À» Á¦ÇÑÇϰí Th17ºÐÈ­¸¦ Áõ°¡½ÃÄ×À¸³ª, ¾à¸®ÇÐÀû(Ȱ¼ºÁ¦¸¦ ¿ÜºÎ¿¡¼­ Åõ¿©) SIRT1 activationÀÇ T¼¼Æ÷ ºÐÈ­ ¹× Ç×Á¾¾ç¹ÝÀÀÀº ºÒºÐ¸íÇß¾ú´Âµ¥, ÀúÀÚµéÀÇ ½ÇÇè°á°ú·Î µå·¯³­ °ÍÀº  SIRT1 pharmacological agonists Åõ¿©·Î »ýÁã¿Í »ç¶÷¿¡°Ô¼­ °øÈ÷ Th17¼¼Æ÷ ºÐÈ­¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦ÇÑ´Ù´Â °ÍÀÓ 
SIRT1 activationÀº Th17¼¼Æ÷³»¿¡¼­ ^STAT3 deacetylationÀ» Â÷´ÜÇÏ¿© ÇÙ³»·ÎÀÇ ÀüÀ§, RorC ÇÁ·Î¸ðÅÍ¿¡ °áÇÕÇÏ¿© Àü»ç À¯µµµÇ´Â ¸ðµç ´É·ÂÀ» °¨¼Ò½ÃÄ×°í ¶ÇÇÑ, Th17¼¼Æ÷ÀÇ IL-17A,F ¹× IL-21, 22, 23R ºÐºñ¸¦ Â÷´ÜÇÔÀ¸·Î½á ±× ÇϺÎÀÇ ¹ÝÀÀµé, Áï VEGF-A »ý»ê-->Á¾¾ç¼ºÀå ¹× Ç÷°ü½Å»ýÀÇ ¸ðµç °úÁ¤À» ¾ïÁ¦½ÃÅ´À¸·Î½á tomor microenvironmemet¸¦ °áÁ¤ÀûÀ¸·Î ¾ïÁ¦ÇÔÀÌ È®ÀεǾúÀ½(wet typeAMD¾ïÁ¦µµ!!) 
SIRT1 agonistsÅõ¿©´Â Th17 cell differentiationÂ÷´ÜÀ» ÅëÇØ °á±¹ »ýÁã¿¡¼­ Á¾¾ç¼ºÀåÀ» °¨¼Ò½ÃÄ×°í ¾ÏȯÀڵ鿡°Ô Åõ¿©ÇÑ SIRT1 agonist ¸ÞÆ®Æ÷¸£¹ÎÀº Th17¼¼Æ÷ÀÇ ºÐÈ­ºóµµ¿Í STAT3 acetylation levelsÀ» ¸ðµÎ ÀúÇϽÃÄ×À½..... °á·ÐÀûÀ¸·Î, SIRT1 activators µéÀº IL-17A±â´ÉÀ» Á÷Á¢ Ÿ°ÙÆÃÇØ¼­ Th17ºÐÈ­¸¦ ¾ïÁ¦ÇÔ ÅëÇØ Á¾¾ç¼ºÀåÀ» ¾ïÁ¦ÇÑ´Ù°í º¼ ¼ö ÀÖÀ½ 
--------------

>>2020.09.25 ¿îµ¿ÀÇ ³î¶ó¿î È¿°ú… Äڷγª19µµ ¾ïÁ¦ÇÑ´Ù°í

±ÙÀ° È£¸£¸ó 'À̸®½Å'ÀÇ ´Ù¾çÇÑ È¿´É

¿îµ¿ÇÏ¸é ±ÙÀ°¿¡¼­ ºÐºñµÇ´Â À̸®½Å È£¸£¸óÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÑ´Ù´Â »ç½ÇÀÌ ¹àÇôÁ³´Ù. ¿îµ¿ÇßÀ» ¶§ ºÐºñµÇ´Â È£¸£¸ó ‘À̸®½Å(Irisin)’ÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÑ´Ù´Â ¿¬±¸°¡ ³ª¿Ô´Ù.

»óÆÄ¿ï·çÁÖ¸³´ë ¹Ì¸®¾Æ³× µ¥ ¿Ã¸®º£À̶ó ¹Ú»çÆÀÀÌ ÇмúÁö 'ºÐÀÚ ¼¼Æ÷ ³»ºÐºñÇÐ(Molecular and Cellular Endocrinology)'¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é ¿îµ¿À» ÇÏ¸é ±ÙÀ°¿¡¼­ ³ª¿À´Â È£¸£¸ó ‘À̸®½Å’ÀÌ Äڷγª19 Ä¡·á È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³´Ù.

¿îµ¿È£¸£¸ó À̸®½Å, Äڷγª19 ¾ïÁ¦ È¿°ú

¿¬±¸ÆÀÀº Äڷγª19 ¹ÙÀÌ·¯½º º¹Á¦¿Í °ü·ÃµÈ 1¸¸4857°³ À¯ÀüÀÚ¸¦ ´ë»óÀ¸·Î À̸®½ÅÀÇ È¿°ú¸¦ ½ÃÇèÇß´Ù.

±× °á°ú, À̸®½Å È£¸£¸óÀÌ TLR3, HAT1, HDAC2 µî À¯ÀüÀÚ ¹ßÇöÀ» ÁÙ¿©, Äڷγª19 ¹ÙÀÌ·¯½º º¹Á¦ÀÇ ÇÙ½É À¯ÀüÀÚ ‘ACE-2’¸¦ ¾ïÁ¦ÇÑ´Ù´Â »ç½ÇÀ» ¹àÇô³Â´Ù. ACE-2 À¯ÀüÀÚ´Â Äڷγª ¹ÙÀÌ·¯½º°¡ ½Åü¿¡ ħÅõÇÏ´Â µ¥ ¾²ÀÌ´Â ¼ö¿ëü´Ù.

¶Ç ¿¬±¸ÆÀÀº À̸®½ÅÀÌ Äڷγª19 ¹ÙÀÌ·¯½º°¡ ½Åü¿¡¼­ º¹Á¦µÇ´Â °ÍÀ» ¸·´Â ‘TRIB3 À¯ÀüÀÚ’ÀÇ º¹»ç ¼öÁØÀ» 3¹è·Î ³ôÀδٴ °Íµµ ¹àÇô³Â´Ù. ¿¬±¸ÆÀÀº “TRIB3 À¯ÀüÀÚ°¡ ºÎÁ·Çϸé Áý´Ü°¨¿°¿¡ ½±°Ô ³ëÃâµÇ´Â µî Äڷγª19 ¹ÙÀÌ·¯½º ¾ïÁ¦¿¡ Áß¿äÇÏ´Ù´Â »ç½ÇÀº ¿©·¯ ¿¬±¸¿¡¼­ ÀÔÁõµÆ´Ù”¸ç “TRIB3´Â ³ªÀ̰¡ µé¼ö·Ï °¨¼ÒÇϹǷΠ°í·ÉÃþÀº ƯÈ÷ ÁÖÀÇÇØ¾ß ÇÑ´Ù”°í ¸»Çß´Ù.

¹ÙÀÌ·¯½º ¾ïÁ¦»Ó ¾Æ´Ï¶ó »À, ³ú ưưÇÏ°Ô ¸¸µé¾î

¿îµ¿È£¸£¸ó À̸®½ÅÀº Äڷγª19 ¹ÙÀÌ·¯½º ¾ïÁ¦»Ó ¾Æ´Ï¶ó Àü½Å¿¡ ´Ù¾çÇÑ °Ç°­ È¿°ú¸¦ ÁØ´Ù°í ¾Ë·ÁÁ³´Ù.

¹Ì±¹ ÇϹöµåÀÇ´ë ºê·ç½º ½ºÇǰָ¸ ±³¼öÆÀÀº 2018³â À̸®½ÅÀÌ »À¸¦ ưưÇÏ°Ô ¸¸µç´Ù´Â »ç½ÇÀ» ¹àÇô³Â´Ù. ¿¬±¸ÆÀÀº ¼¼Æ÷½ÇÇèÀ» ÅëÇØ À̸®½ÅÀÌ À¯ÇØÇÑ °ú»êÈ­¼ö¼Ò·ÎºÎÅÍ °ñ¼¼Æ÷¸¦ º¸È£Çϰí, »À¸¦ ´Ù½Ã ¸¸µå´Â ‘½ºÅ¬·¹·Î½ºÆ¾ ´Ü¹éÁú’ »ý»êÀ» ´Ã¸°´Ù´Â »ç½Çµµ Áõ¸íÇß´Ù.

À̸®½ÅÀº Ä¡¸Åµµ ¿¹¹æÇÏ´Â È¿°ú°¡ ÀÖ´Ù. ¹Ì±¹ Ä÷³ºñ¾Æ´ëÇÐ ÀÇ´ë ¿ÀŸºñ¿À ¾Æ¶õ½Ã¿À ¹Ú»çÆÀÀº 2019³â ±â¾ïÀ» ´ã´çÇÏ´Â ‘ÇØ¸¶’¿¡ À̸®½ÅÀÌ Á¸ÀçÇϰí, Ä¡¸Å ȯÀÚ ÇØ¸¶¿¡´Â Á¤»óÀκ¸´Ù À̸®½ÅÀÌ Àû´Ù´Â »ç½ÇÀ» ¿¬±¸¸¦ ÅëÇØ ¹àÇô³Â´Ù.

¿¬±¸ÆÀÀÌ ÁãÀÇ ÇØ¸¶¿¡¼­ À̸®½ÅÀ» ¾ø¾ÖÀÚ ³ú¿¡¼­ ½ÅÈ£Àü´Þ ±â´ÉÀ» ÇÏ´Â '½Ã³À½º'°¡ ¾àÇØÁö¸é¼­ ±â¾ï·ÂÀÌ ¶³¾îÁö´Â °ÍÀ» È®ÀÎÇß´Ù. ¹Ý´ë·Î À̸®½ÅÀ» ´Ã¸®ÀÚ ½Ã³À½º ±â´É°ú ±â¾ï·ÂÀÌ È¸º¹µÆ´Ù. ÇöÀç Ä÷³ºñ¾Æ´ëÇÐ ¿¬±¸ÆÀÀº À̸®½ÅÀ» Ä¡¸Å Ä¡·á¿¡ Àû¿ëÇÏ´Â ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ´Ù.

À̸®½ÅÀº Áö¹æÀ» ‘°¥»öÁö¹æ’À¸·Î ¹Ù²ã üÁßÀ» °¨¼Ò½ÃŰ´Â È¿°úµµ ÀÖ´Ù. Áß¼ºÁö¹æ°ú ÁöÁú·Î ÀÌ·ïÁø ‘¹é»öÁö¹æ’ÀÌ ¿°ÁõÀ» ÀÏÀ¸Å°´Â °Í°ú ´Þ¸®, °¥»öÁö¹æÀº Ç÷´çÀ» ºÐÇØÇϰí, üÁß Á¶Àý¿¡ µµ¿òÀ» ÁØ´Ù. ¶Ç À̸®½ÅÀº ¸é¿ªÃ¼°è¸¦ ÀÛµ¿½ÃŰ´Â ‘»çÀÌÅäÄ«ÀÎ’À» ¹æÃâÇÏ°í ¿°ÁõÀ» Àâ¾Æ¸Ô´Â ‘´ë½Ä¼¼Æ÷’µµ Ȱ¼ºÈ­½ÃÄÑ ¹ÙÀÌ·¯½º·ÎºÎÅÍ ¸öÀ» º¸È£ÇØÁØ´Ù.

À̹ø ¿¬±¸¿¡¼­ ¿Ã¸®º£À̶ó ¹Ú»çÆÀÀº Áö¹æ Á¶Á÷ÀÌ ‘Äڷγª19 ¹ÙÀÌ·¯½º ÀúÀå¼Ò’·Î ¾²Àδٴ °Íµµ ¹ß°ßÇß´Ù. ¿¬±¸ÆÀÀº “ºñ¸¸ÀÎ »ç¶÷Àº ÀϹÝÀκ¸´Ù À̸®½Å ¼öÄ¡°¡ ³·°í, ACE-2 ¼ö¿ëü ¼öÄ¡°¡ ³ôÀº °æÇâÀÌ ÀÖ´Ù”¸ç “ÀÌ´Â ºñ¸¸ÀÎ »ç¶÷¿¡°Ô ½É°¢ÇÑ Áúº´ÀÌ ¹ß»ýÇÒ À§ÇèÀÌ ´õ Å©´Ù´Â °ÍÀ» º¸¿©ÁØ´Ù”°í ¸»Çß´Ù. 

¿îµ¿À» ÅëÇØ À̸®½ÅÀÌ ºÐºñµÇ¸é Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ°í, Áõ»óÀ» ¾ÇÈ­ÇÏ´Â ºñ¸¸±îÁö °³¼±ÇÏ´Â ÀÌÁß È¿°ú°¡ ÀÖ´Ù°í ¼³¸íÇß´Ù. ¿Ã¸®º£À̶ó ¹Ú»ç´Â “À̹ø ¿¬±¸´Â Äڷγª19 Ä¡·áÀÇ ½Ç¸¶¸®¸¦ ¹ß°ßÇÑ °Í”À̶ó¸ç “À̸®½ÅÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾î¶»°Ô Á¶ÀýÇÏ´ÂÁö ÆÄ¾ÇÇÏ´Â Ãß°¡ ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù”°í ¸»Çß´Ù.

===========

[[Can Activation of NRF2 Be a Strategy against COVID-19]]

[[SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate]]

 

**((ÃÖÁ¾Á¤¸®))nrf2 down-regulation, IFN-1°¨¼Ò//ACE2¹ßÇöÁõ°¡, TGF-1betaÁõ°¡, TLR-4Áõ°¡°¡ Ư¡ÀÎ COVID19°¨¿°½Ã nrf2 activators Åõ¿©·Î ¾ò´Â ÀÕÁ¡µé^^1)ù¹øÂ° È¿°ú´Â free nrf2Áõ°¡·Î ¼¼Æ÷¸·ÀÇ ACE2¹ßÇöÀÌ °¨¼Ò, ±× °á°ú ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ ¹ÙÀÌ·¯½ºÄ§ÀÔÀ» ¾ïÁ¦ÇÔ, ÇÑÆí, nrf2 activator Åõ¿©È¿°ú´Â Ç×¹ÙÀÌ·¯½º¹ÝÀÀ°ú °ü·ÃµÈ IFNȰ¼º°ú ÀüÇô ¹«°üÇÔ(nrf2´Â ¿ø·¡ ACE2Áõ»ê ¹× ¼¼Æ÷¸· ¹ßÇöÀ» ¾ïÁ¦ + ÀÎÅÍÆä·ÐÀ¯ÀüÀÚÀÚ±ØÃ¼(STING) ¹× IRF3 ¹ßÇöÀ» ¾ïÁ¦ÇÔ=IFN°¨¼Ò...IFN-1ÀÇ Ç×¹ÙÀÌ·¯½º±âÀü±îÁö °í·ÁÇÑ´Ù¸é VC¸¦ ÇÔ²² Åõ¿©ÇÏ´Â °ÍÀ» °í·Á!!...nrf2 activatorÀÛµ¿±âÀüÀº ·½µ¥½Ãºñ¸£³ª HCQÀÛµ¿±âÀü°ú °ãÄ¡Áö¾ÊÀ½ÀÌ È®ÀεǾúÀ½!!).....ÀÚ¼¼È÷ º¸¸é, p62-induced nrf2 activation°ú À¯»çÇÏ°Ô ÀÛ¿ëÇÔ...¼¼Æ÷Áú³» Protein kinase R(PKR)ÀÌ p62¸¦ ÀÛµ¿ÇÏ¿© keap1-nrf2º¹ÇÕü»óÅ¿¡¼­ nrf2 inhibitorÀÎ keap1À» Å»¶ô½Ãzl°í ±× °á°ú Áõ°¡µÈ free nrf2°¡ ÇÙ³»·Î À̵¿ÇÏ¿© Àü»çµÊ, À̷νá AREÀ¯ÀüÀڷκÎÅÍ Ç×»êÈ­È¿¼Ò ¹× Á¦2»óÇØµ¶°ü·ÃÈ¿¼Ò°¡ Áõ»êµÇ°í ^^2)±× °á°ú  ¹ÙÀÌ·¯½º°¨¿°À¸·Î ÃË¹ßµÈ ¿°ÁõÇâ»çÀÌÅäÄ«ÀÎ ¹× ¿°Áõ°ü·Ã¹°ÁúÀÇ ÆøÁõÀ¸·Î ¾ß±âµÇ´Â (TGF-1beta°æ·Î)CSS/ARDS, (TLR-4°æ·Î°ü·Ã)sepsis/MODSµîÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ°Ô µÊ... ±× Áß¿¡¼­ antioxidant HO-1Àº (PKR-eIF2 °æ·ÎȰ¼º°ú ÇÔ²²) ¹ÙÀÌ·¯½º»ç¸ê±âÀüÀ» ÇÔ²² ÁÖµµÇϰí Àֱ⿡ °¡Àå Áß¿ä......^^3)HO_1Àº ¹ÙÀÌ·¯½ºº¹Á¦ÀÇ ¸ðµç °úÁ¤À» ¾ïÁ¦½Ãų»Ó ¾Æ´Ï¶ó »ç¸êÀ» À¯µµÇϰí Àִµ¥, hemeÀ» »êÈ­ÇÏ¿© biliverdin, CO, Fe2+·Î ºÐÇØÇϰí BVÀº ¹ÙÀÌ·¯½ºÆú¸®ÆéƼµåÀÇ ¼º¼÷À» Â÷´Ü, CO´Â NOX¾ïÁ¦°æ·Î·Î ROS»ý¼ºÂ÷´Ü, fe2+´Â ¹ÙÀÌ·¯½ºÀÇ RNApolymerase¸¦ Â÷´ÜÇÔÀ¸·Î½á °á±¹ ¹ÙÀÌ·¯½º»ç¸êÀ» À¯µµÇϰí ÀÖÀ½ ...¶ÇÇÑ, ¼¼Æ÷Áú³» PKRÀº nrf2Ȱ¼º À¯µµÀÛ¿ë¿¡ ´õÇÏ¿© ¼ÒÆ÷ü(ER)¿¡ ÀÖ´Â PKR-À¯»ç kinaseÀÇ È°¼º °øÁ¶¸¦ ÅëÇØ eIF2(À¯ÇÙ¼¼Æ÷°³½ÃÀÎÀÚ)¸¦ ÀλêÈ­½ÃÅ´À¸·Î½á ¹ÙÀÌ·¯½ºpolymeraseÀÇ ¹ø¿ªÀ» ¾ïÁ¦ÇÏ¿© ¹ÙÀÌ·¯½ºÀÇ ºñ±¸Á¶´Ü¹é »ý»ê--genome º¹Á¦ ¹× viral mRNAÀü»ç/¹ø¿ª ÅëÇÑ ¹ÙÀÌ·¯½º ±¸Á¶´Ü¹é »ý»ê ¾ïÁ¦±îÁö ´ã´çÇϰí ÀÖÀ½ 

*¹ÙÀÌ·¯½º°¨¿°¿¡ ´ëÇÑ  °¡Àå Áß¿äÇÑ ¼±Ãµ¸é¿ª¹ÝÀÀÀ¸·Î¼­ ¼÷ÁÖ¼¼Æ÷ÀÇ IFN-1»ý»ê¹ÝÀÀÀº ÆÐÅÏÀνļö¿ëü(PRR)ÀÇ È°¼º ÅëÇØ ¹ß»ýµÊ.. RNA¹ÙÀÌ·¯½ºÀÇ °æ¿ì, ¹ÙÀÌ·¯½ºRNA¿Í RNApolymerase¸¦, retinoic acid inducible gene I (RIG-I)-like receptors°¡ ¸ÕÀú, ±×¸®°í °ð melanoma differentiation associated protein 5(MDAP5)°¡ °¨ÁöÇÏ°í  mitochondrial antiviral-signaling protein (MAVS=IFN-beta promotor stimulator IPS-1)°ü·Ã ¸ðÁý¹ÝÀÀÀ» ÀÏÀ¸Å´.....ÇÑÆí, DNA¹ÙÀÌ·¯½ºÀÎ °æ¿ì, ¹ÙÀÌ·¯½º DNA´Â DEAD-box protein (DDX) 41, cyclic GMP-AMP synthase (cGAS), ¹× γ-IFN-inducible protein 16 (IFI16)¿¡ ÀÇÇØ °¨ÁöµÇ¸ç ÀÌ ¸ðµÎ´Â °á±¹stimulator of IFN genes (STING)ÀÇ È°¼ºÀ» À¯µµÇÔ ..... MAVS¸ðÁý ¹× STING Ȱ¼ºÀº TANK-binding kinase 1 (TBK1)ÀÇ Ãß°¡¸ðÁý ¹× IRFÀÇ ÀλêÈ­¸¦ À̲ø¾î³»°í  ÇÙÀ¸·Î À̵¿½ÃÄÑ IFNÁõ»ê¿¡ ÀÏÂ÷ÀûÀ¸·Î ¹ÝÀÀÇÏ´Â IFN regulatory factors (IRFs)ÀÇ Àü»çȰ¼ºÀ» À¯µµÇÔ.... ¼¼Æ÷Áú³» RNA polymerase III ´Â ¿ÜºÎ¿¡¼­ À¯ÀÔµÈ foreign and aberrant DNA¸¦ RNA·Î Àüȯ½Ã۰í, RIG-1Àº RNAÀÇ 3ÁßÀλêÀ» °¨ÁöÇϱ⠶§¹®¿¡ RNA polymerase III´Â RIG-1°æ·Î ÅëÇØ ÀϾ´Â ¼±Ãµ¸é¿ª¹ÝÀÀÀ» °³½ÃÇÏ´Â DNA¼¾¼­·Î ¿ªÇÒÀ» ÇÔ... Áõ»êµÈ IFNÀº ¼¼Æ÷¿¡¼­ ºÐºñµÇ¾î IFNAR1 / 2¿¡ °áÇÕÇÏ¿© JAK / STAT Ȱ¼ºÈ­¸¦ À¯µµÇϰí Ȱ¼ºÈ­ µÈ interferon stimulated geneÀÎ ISGF3 trimer ¶Ç´Â STAT1 dimer´Â ISRE ¶Ç´Â GAS ¼­¿­¿¡ °áÇÕÇÏ¿© ¾à300¿©°³ÀÇ ISGÀÇ ¹ßÇöÀ» ÃËÁøÇÔÀ¸·Î½á ¹ÙÀÌ·¯½ºµéÀ» ¾ïÁ¦ÇÔ....¹ÙÀÌ·¯½º´Â °¢ÀÚ ³ª¸§´ë·ÎÀÇ Æ¯ÀÌÇÑ ´ë󹿽ÄÀ» °³¹ßÇØ³»¾î ÀÎÅÍÆä·ÐÀÇ °ø°ÝÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£Çϰí ÀÖÀ½

*HSV´Â DNA¹ÙÀÌ·¯½º·Î¼­ ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀº IFN-1ÀÌ ÃæºÐÇÒ ¶§ ´õ ¿Õ¼ºÇÑ Æ¯¼ºÀ» °¡Áö´Â ¹Ý¸é, COVID19´Â RNA¹ÙÀÌ·¯½ºÀε¥, ħ½À Ư¡Àº ³»Àμºnrf2 ÀúÇϸ¦ ÅëÇØ  IFN-1 »ý»êºÐºñ ÀúÇÏ, ¹Ý¸é ¼¼Æ÷¸·ÀÇ ACE2Áõ°¡µÉ ¶§ ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀÌ ¿Õ¼ºÇÏ°Ô µÇ´Â Â÷º°¼ºÀÌ ÀÖÀ½.....RNA¹ÙÀÌ·¯½º´Â ħ½ÀÃʱ⿡ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ³»Àμºnrf2ÇÏÇâÁ¶Àý, ÀÌ¿¡ µû¸¥ ¼¼Æ÷¸·ACE2Áõ°¡ ¹× IFN-1°¨¼Ò(¹ÙÀÌ·¯½ºÀÇ nucleocapsidÅ»°¢½ÅÈ£¿¡ µû¸¥ (IFN-1À» »ý»êÇÏ´Â)STING¹ÝÀÀ ¹ßÇöÀ» ÇÏÇâÁ¶ÀýµÈ nrf2°¡ °¨¼è ¹× Áö¿¬½ÃÅ´...±×·¯³ª, ÀÌ Çö»óÀº ¹ÙÀÌ·¯½ºgenomeº¹Á¦½ÃÁ¡ÀÌÈÄ autophagy³»¿¡¼­ keap1ÀÌ Å»¶ôµÈ »óÅ·Π¼¼Æ÷Áú³»·Î À¯¸®µÈ free nrf2ÀÇ ÀÚ±ØÀ¸·Î ÀÎÇØ ±Øº¹ÀÌ µÇ´Âµ¥, ÀÌ ¶§´Â ¿ÀÈ÷·Á STINGȰ¼º ¹×  IRF3Àü»çȰ¼ºÀ¸·Î ÀÎÇÑ IFN-1ÀÇ Áö¿¬¼º, °ú´ÙºÐºñÇö»óÀ» À¯¹ßÇÔ

=**¼¼Æ÷³» ³»Àμºnrf2 ÀÛ¿ëÀº Æò¼Ò¿¡´Â ¼¼Æ÷¸· ACE2¹ßÇö ¾ïÁ¦ + IFN-1»ý¼º°ü·Ã STINGÀü»ç¹ßÇö¾ïÁ¦ÇÔ(IFN-1Áõ°¡½Ã ¶Ç´Â nrf2Ȱ¼ºÁõ°­½Ã ¼¼Æ÷¸·ÀÇ ACE2¹ßÇöÀº °¨¼ÒÇÔ!!)....ACE2°ÅÃÄ ¼÷ÁÖ¼¼Æ÷³»·Î µé¾î¿Â ¹ÙÀÌ·¯½º nucleocapsid uncoating ¹× ¹ÙÀÌ·¯½º´Ü¹éÁõ»ê½ÅÈ£·Î ÀڱعÞÀº cGAS/STING¹ßÇöÀ» ³»Àμºnrf2´Â °¨¼è¹ÝÀÀÀ¸·Î °è¼Ó repressingÀ¯ÁöÇÔ (=±× °á°ú, IFN-1,3»ý»ê¾ïÁ¦, ¹Ý¸é¿¡ ACE2»ý»êÀº Áõ°¡)......¹ÙÀÌ·¯½ºgenomeº¹Á¦°¡ ¹ß»ýµÇ¸é¼­ ºñ·Î¼Ò ¿ÀÅäÆÄÁö¿¡¼­ ¼¼Æ÷Áú·Î À¯¸®µÈ free NRF2´Â of HO-1 »ý»êÇÏ¿© ±× °á°ú ^^¹ß»ýµÈ Fe2+´Â divalent metal-binding pocket of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV2¿¡ °áÇÕÇÏ¿© genomeº¹Á¦¸¦ ¾ïÁ¦((ºô¸®º£¸£µòÀº ±¸Á¶´Ü¹é ¼º¼÷ ¾ïÁ¦, fe2+´Â RNAº¹Á¦ Â÷´Ü, CO´Â NOX¾ïÁ¦ ÅëÇØ ROS¹ß»ýÂ÷´Ü)), ^^HO-1Àº ÀλêÈ­°ÅÃÄ IRF3¿Í °áÇÕÇÏ¿© Àü»çµÊÀ¸·Î½á IFN-1»ý»êÀÌ Àç°³µÊ....ÇÑÆí, ¹ÙÀÌ·¯½º±¸Á¶´Ü¹é ¹ø¿ª´Ü°è¿¡¼­´Â  ¼÷ÁÖ¼¼Æ÷³»ÀÇ double-stranded RNA-activated protein kinase R (PKR)°¡ ÀÛµ¿µÇ¾î eIF2¸¦ ÀλêÈ­ÇÔÀ¸·Î½á ¹ÙÀÌ·¯½º±¸Á¶´Ü¹é Áõ»ê ¾ïÁ¦ + PKRÀÛµ¿Àº p62¸¦ ÀλêÈ­½ÃÄѼ­ nrf2-keap1º¹ÇÕüÀÇ ¿ÀÅäÆÄÁö¸¦ ÃËÁø, À¯¸®nrf2¸¦ ¼¼Æ÷Áú³»·Î ¹æÃâ, nrf2Ȱ¼ºÀ» º»°ÝÀç°³½ÃÅ´

=Nrf2Ȱ¼ºÁ¦´Â ÁÖ·Î keap1ÀÌ nrf2¿¡ °áÇÕÇÏ´Â °ÍÀ» Â÷´ÜÇϰųª nrf2-keap1º¹ÇÕü·ÎºÎÅÍ keap1Å»¶ôÀ» À¯µµÇÔÀ¸·Î½á nrf2Ȱ¼ºÀ» ÃËÁø½ÃÅ´....³»Àμº Ç×»êÈ­Á¦ »ý»ê ÃËÁø ¹× Th1°æ·Î¾ïÁ¦/Th2°æ·Î Ȱ¼º, NFkBÀü»çÂ÷´Ü ÅëÇØ Ç׿°ÀÛ¿ëÀ» ³ªÅ¸³¿À¸·Î½á ´Ù¾çÇÑ ¸¸¼º¿°ÁõÁúȯġ·áÁ¦·Î »ç¿ë°¡´É ....´õºÒ¾î sirt1 Ȱ¼ºÁ¦´Â innate immunity°ü·Ã Th-17AÂ÷´Ü(ÀÚ°¡¸é¿ªÁúȯ Ä¡·á), Ÿ°ÙÀ¯ÀüÀÚ¿¡¼­ NFkBÀü»çÂ÷´ÜÀÛ¿ëÀ» ³ªÅ¸³¿.

-----------

===¾ÏÁٱ⼼Æ÷½ÅÈ£3ÃÑ»ç : Wnt, Hedgehog, Notch --À̵éÀÌ »ó½Â½Ã ¾Ï¹ß»ý ÃËÁø..==>¾ÏÁٱ⼼Æ÷ Ç¥Àû »ç¸ê È¿°ú°¡ ÀÔÁõµÈ ¿µ¾ç¼Ò ¹× ÇÇÅäÄɹÌÄ®µé·Î¼­´Â. vit.D3, EGCG. Sulforaphan, Curcumin, Piperine. Silibin (Silibin30mgÀº Silymarin70mg¿¡ ÇÊÀû). ±× ¿Ü>Á¦´Ï½ºÅ×ÀÎ, ·¹½ºº£¶óÆ®·Ñ, Äõ¼¼Æ¾, DIM, ÆÄ¸£Å׳î¶óÀ̵å(¿©¸§Èò±¹È­ÀÙÃßÃâ¹°) 

==ÀÏÁ¾ÀÇ STING disorder°¡ Ư¡ÀÎ COVID19°¨¿°¿¡¼­ Nrf2 activator »ç¿ë±Ù°Å :[[NRF2 activatorÀÇ COVID19 ¼¼Æ÷³»Ä§½À ¾ïÁ¦, º¹Á¦ ¾ïÁ¦/ų¸µ À¯µµ,  ¿°Áõ ÆøÁõ/»çÀÌÅäÄ«ÀνºÅè-ARDS ¹× MODS µî ÇÕº´Áõ ¾ïÁ¦ ¸ñÀû]] 

.....COVID-19´Â Á¦ÀÏ ¸ÕÀú ü³»/¼¼Æ÷³» NRF2¸¦ ¾ïÁ¦ÇÔ(ȯÀÚÀÇ Æó »ý°Ë°üÂû°á°ú NRF2 °æ·Î ¾ïÁ¦ -->¼¼Æ÷¸·ÀÇ ACE2»óÇâÁ¶Àý À¯µµ), ¶ÇÇÑ, Nrf2 activatorÅõ¿©´Â SARS-CoV2ÀÇ º¹Á¦¿Í ¿°Áõ ¹ÝÀÀ ÁõÆøÀ» ¾ïÁ¦ÇÔ----±× »ó¼¼±âÀüµéÀº 

**Nrf2Ȱ¼º ÅëÇØ ¼¼Æ÷¸·ÀÇ ACE2Á÷Á¢ ÇÏÇâÁ¶Àý(¹ÙÀÌ·¯½ºÄ§ÀÔ Â÷´Ü) 

**1Çü IFN ÇÏÇâÁ¶Àý(IFN-1ÀÇ Áö¿¬¼º°ú´ÙºÐºñ + NFkBȰ¼º°ú´Ù·Î ¾ß±âµÇ´Â »çÀÌÅäÄ«ÀνºÅè ¹æÁö :: ¹ÙÀÌ·¯½º°¡ ¾ß±âÇÑ IFNÀ¯ÀüÀÚÀÚ±ØÃ¼(STING)ÀÇ È°¼ºÅëÇÑ IRF3»ý¼º-1ÇüIFNÀÇ Áö¿¬¼º °ú´Ù»ý»ê ±âÀüÀÇ Â÷´Ü ÅëÇØ)

**HO-1Ȱ¼ºÀ¯µµ(HO-1Àº hemeÀ» biliverdin, fe++, CO·Î ºÐÇØ :: ºô¸®º£¸£µòÀº viral ÇÁ·ÎÅ×¾ÆÁ¦¸¦ ºÐÇØ, fe++´Â ¹ÙÀÌ·¯½ºº¹Á¦ Â÷´Ü, CO´Â ÀÌÂ÷ÀûÀÎ ROS»ý¼º-¿°Áõ ¹ß»ý¾ÇÈ­ Â÷´Ü..fe++¿ÍCO´Â NFkB¾ïÁ¦), 

**¹«³ÊÁø REDOX Ç×»ó¼ºÀ» ȸº¹½ÃÅ´ 

**NRF2ÀÇ ÀλêÈ­ ÅëÇØ ER¿¡¼­ free pERKÀÚ±Ø ÅëÇØ ¹ÙÀÌ·¯½º mRNA¹× ±¸Á¶¹° º¹Á¦ÀÇ ¸ðµç °úÁ¤¸¶´ÙÀÇ ½ºÀ§Ä¡ ¿ÀÇÁ(pERK.[ER¿¡ À§Ä¡ÇÑProtein KinaseR-À¯»ç kinase]´Â eIF2[À¯ÇÙ¼¼Æ÷°³½ÃÀÎÀÚ]ÀÇ ÀλêÈ­¸¦ À¯µµ, ÀÌ p-eIF2°¡ ¹ÙÀÌ·¯½ºÁßÇÕÈ¿¼ÒÀÇ Àü»ç¸¦ Â÷´Ü + ¹ÙÀÌ·¯½ºÀ¯ÀüÀÚ º¹Á¦ Â÷´Ü + ¹ÙÀÌ·¯½º mRNA Â÷´ÜÇÔÀ¸·Î½á ´Þ¼º) 

==[[Ç׳ëÈ­ = °á±¹ Ç׿°ÀÛ¿ë ¹× ¿°Áõ°³¼±ÀÌ Áß¿ä]] p38MAPK-->COX2, NFkB-->COX2 °æ·Î ÀÌÁßȰ¼º°á°ú ¿°Áõ¹°ÁúÀÌ °ú´Ù»ý¼ºµÇ°í, ÀÌ·Î ÀÎÇÑ Àü½Å±â°ü ³ëÈ­ ¹× ºÎ½ÅÀÇ ¼ºÈ£¸£¸ó»ý»ê°¨¼Ò·Î ¼º±â´ÉÀÌ»ó À¯¹ßµÊ

===========
**AREÀü»ç°á°ú »ý»ê´Ü¹éÁúµé : NQO1(.ȯ¿ø/Á¦µ¶), HO-1(Ç×»êÈ­, Ç׿°, Á¦±Õ), UDP-GT(¾àÁ¦/µ¶¼Ò Á¦µ¶ ¹× ¹èÃâ), Mrps(¾àÁ¦³»¼º),  SRXN1/TXNRD1(°ú»êÈ­¼ö¼Ò/Áú¼Ò»êÈ­¹° Á¦°Å), GCLC/GCLM(GSH»ý»ê), glutathione S-transferase(Á¦µ¶ÈÄ GSHÀç»ý)
-----------
[[NAD+-dependent deacetylaseÀÎ SIRT1 ¼¼Æ÷ ½ÅÈ£ Àü´Þ °æ·Î....SIRT1/ AMPK / PGC-1 α °æ·Î Ÿ°ÙÆÃ....SIRT1 activatorsÀåÁ¡]]
**1)AMPK(AMP-activated protein kinase)Ȱ¼º ÃËÁø½ÅÈ£ : »êÈ­½ºÆ®·¹½º ¹× LKB1(Ser-Thr liver kinase B1 : sirt1ÀÇ »ó´ëÀû ºÎÁ·À» °¨ÁöÇϰí ÀÛµ¿µÊ...AMPK°æ·Î ÀÚ±ØÃ¼ )ÀÚ±ØÀ¸·Î AMPK´Â Ȱ¼ºµÇ¾î ¹ÌÅäÄܵ帮¾Æ »ý»êÁõ°¡+Áö¹æ»ê»êÈ­+Àν¶¸°¹Î°¨µµ »óÇâÁ¶ÀýÀ¯µµ
**2)NAD+/NADHºñÀ² »óÇâ ½ÅÈ£
**3)SIRT1 Ȱ¼º½ÅÈ£ :
^AMPK»óÇâÁ¶ÀýÀ¯µµ½ÅÈ£µéÀÌ Áß¿äÇѵ¥,  NAD+/NADH ºñÀ² »óÇâ½ÃÅ´À¸·Î½á ¹ß»ýÇÏ´Â ½ÅÈ£ ¹× DNA¼Õ»ó ½ÅÈ£´Â SIRT1 Ȱ¼ºÀ» ÀÚ±ØÇÔ, ¶ÇÇÑ ¶§¶§·Î »êÈ­½ºÆ®·¹½ºÀÚü°¡ SIRT1»ý»êÀ» ÀÚ±ØÇÔÀ¸·Î½á SIRT1»óÇâÁ¶ÀýÀÌ ¹ß»ý, ±× °á°ú LKB1Å»¾Æ¼¼Æ¿È­ ÅëÇØ AMPK¸¦ Ȱ¼º½Ã۰í NAD+/NADH ºñÀ²À» ÀúÇϽÃŰ´Â ¾ç¼ºÇǵå¹éÁ¶Àý°è¸¦ Çü¼ºÇÔ, ±âŸ SIRT1 Ȱ¼º°ü·Ã±âÁ¦µéÀ» º¸¸é..
^SIRT1Ȱ¼º°á°ú, PPAR-gamma coactivator-1alpha(PGC-1α)ÀÚ±Ø..[±×°á°ú ¹ÌÅä.»ý»êÃËÁø+ÁöÁúÆ÷µµ´ç Ç×»ó¼º À¯Áö+Ç×»êÈ­¹æ¾î·ÂÀ¯Áö¿¡ °ü¿©..PGC1a´Â nrf1, nrf2ÀÇ È°¼º°øÁ¶ÀÚÀ̸鼭 µ¿½Ã¿¡ ¹ÌÅä.»ý»ê +´çºÐ/ÁöÁú ºÐÇØ ÀÌ¿ëÀÇ ÁÖ¿äÁ¶ÀýÀÚÀÓ...Ç×»êÈ­Á¶ÀýÀº nrf2, FOXO3a, PGC1apha¿¡ ´ëÇÑ SIRT1Ȱ¼º°á°úÀÌ¸ç Æ¯È÷ FOXO3a¿Í PGC1alphaÀÇ Å»¾Æ¼¼Æ¿È­ °ÅÃÄ ÀÌ·ç´Â º¹ÇÕü´Â MnSOD.CAT¸¦ Áõ»ê½ÃÅ´...NAFLD¹× hepatic steatosis½Ã SIRT1 activatorsÀÎ ·¹½ºº£¶óÆ®·Ñ/Äõ¼¼Æ¾ ¹× ¾ËÆÄ¸®Æ÷ÀÍ»êÀ» Åõ¿©ÇÏ´Â ±Ù°Å´Â cAMP-PRKA-AMPK-SIRT-PGC1alpha½ÅÈ£°æ·ÎȰ¼º½ÃÅ´À¸·Î½á ÀϾ´Â Áö¹æ»ê»êÈ­À¯µµ ¹× ¿ÀÅäÆÄÁö ¹× Ç×»êÈ­¹°Áú»ý»êÀÛ¿ëÀ» ÅëÇØ °³¼±½Ã۱⠶§¹®ÀÓ...¼ÒÈ­Àå¾Ö¿¡ À־µµ SIRT1Àº µ¿ÀÏÇÑ ±âÀüÀ¸·Î ÀÛµ¿µÈ´Ù°í ¿©°ÜÁü],
^p53À» ¾ïÁ¦..[±× °á°ú ¾Ï¹ß»ý¾ïÁ¦ + ¼¼Æ÷ÀÚ»ìÁ¶ÀýÀ» ¼öÇà...°£¾ÏÁٱ⼼Æ÷´Ü°è¿¡¼­´Â »ó½ÂµÇ¾ú´ø SIRT1Àº ¾ÏÁٱ⼼Æ÷ÀÇ ºÐÈ­°úÁ¤¿¡¼­´Â ÀúÇϵǴ Çö»óÀ» º¸À̸ç, ¿ÜºÎ¿¡¼­ SIRT1Ȱ¼ºÁ¦Åõ¿©·Î ÀÎÇÑ SIRT1°ú¹ßÇöÀº ¾ÏÁٱ⼼Æ÷°¡ ¾Æ´Ñ ¾Ï¼¼Æ÷µéÀÇ self-renewalÀ» ȸº¹½Ã۸ç ÀÌ °úÁ¤¿¡ °ü¿©ÇÏ´Â Á¶ÀýÀÚ´Â SOX2¶ó´Â °ÍÀÌ ¹àÇôÁ®¼­ HCCÄ¡·á¿¡ SIRT1Ȱ¼ºÁ¦¸¦ Åõ¿©ÇÏ´Â ±Ù°Å°¡ µÊ],
^NFkB¸¦ ¾ïÁ¦..[¼¼Æ÷ÇÙÀ¯ÀüÀÚºÎÀ§¿¡¼­ Àü»çÂ÷´Ü°úÁ¤À¸·Î ¿°ÁõÁ¶Àý...THF-alpha, IL-1β, and IL-6 µî  proinflamm.cytokines Àü»ç¹ßÇö ¾ïÁ¦..histones,  transcription factors NF-kB  and AP-1 µîÀ» Å»¾Æ¼¼Æ¿È­...IBDÄ¡·á¿¡ Áß¿ä .],
^UCP2(uncoupling protein2gene) Àç¾ïÁ¦.. [SIRT1Àº ÃéÀ庣Ÿ¼¼Æ÷¿¡¼­ ¿ø·¡ E2F1Àü»çȰ¼ºÀ» ¾ïÁ¦ÇÏÁö¸¸, E2F1ÀúÇÏ´Â SIRT1¹ßÇöÀ» ¿ÀÈ÷·Á »óÇâÁ¶ÀýÇÔ, ¹Ý¸é¿¡ SIRT1Ȱ¼ºÀº Àν¶¸°ºÐºñ¸¦ ¾ïÁ¦(±×·Î ÀÎÇØ ¿­»ý¼ºÁõ°¡, ÁöÁúÃàÀû, ºñ¸¸À¯µµ)Çϰí ÀÖ´Â UCP2¸¦ Àç¾ïÁ¦ÇÔÀ¸·Î½á Àν¶¸°ºÐºñ ÃËÁø/¹Î°¨µµ Çâ»ó]
**[[Regeneration and Aging: Regulation by Sirtuins and the NAD+ Salvage Pathway]]
°íÁö¹æ½ÄÀÌ ¼·Ãë½Ã´Â NAD+¼Ò¸ð Áõ´ë, °á°úÀû °¨¼Ò°¡ À¯¹ßµÇ¾î (´ç´¢º´¼º ¸»ÃʽŰ濰¿¡¼­ º¸µí) »êÈ­ÀλêÈ­ÀÇ ÀúÇÏ-ÁöÁúÃàÀû-½Å°æaxon¼Õ»óÀÌ À¯¹ßµÇ´Âµ¥, ´ÏÄÚÆ¾¾Æ¹Ìµå¸ð³ë´ºÅ¬·¹¿ÀƼµå((³ªÀ̾ƽžƹ̵å, ´ÏÄÚÆ¾¾Æ¹Ìµå))¸¦ Åõ¿©ÇÏ¸é °íÁö¹æ½ÄÀÌÁß´Ü ¾øÀ̵µ ¿ªÀ¸·Î  NAD+°¡ Áõ»êµÇ¾î »êÈ­ÀλêÈ­ ȸº¹-ÁöÁúÃàÀû ÇØ¼Ò-½Å°æÃà»è ¼Õ»óȸº¹À» º¼ ¼ö ÀÖ¿È
======vitamin D °ø±Þ½Ã SIRT1, irisin, BDNF Áõ»ê + IR °³¼±(ºñ¸¸ 2ÇüDM)======
**[[COVID19+INFLUENZA twindemic ]] 1Çü ÀÎÅÍÆä·Ð Áõ»ê±îÁö °í·ÁÇÑ ¹æÃ¥.
>>°¨¿°È®ÁøÀÚ ::: ÇÇ¶ó¸Æ½º 3ÀÏ¿ä¹ý ¶Ç´Â ´ÙÀ½ÀÇ combination therapy  5ÀÏ¿ä¹ý---- ¾ÈÅä½Ã¾È 1000mg#2(for IFN-1) + HCQ 800mg #2 + artemisinin 800mg #2 + bromelain 200mg #2 + EGCG/curcumin/ silymarin/ sulforaphan/piperine 4T #2 (for SIRT1 activator and nrf2 activator  ::: act-N)...±× ÀÌÈÄ ¿¹¹æ¿ä¹ýÀ¸·Î º¹±Í
>>°¨¿°¿¹¹æ : (ÁÖ1ȸ ÇÇ¶ó¸Æ½º.. 3ÁÖ°£ ÈÄ 1 ÁÖ ÈÞ¾à) ¶Ç´Â (ÁÖ1ȸl)HCQ 400mg + (¸ÅÀÏ1ȸ) ¾Æ¸£Å×¹Ì½Ã´Ñ 100mg + ¼¿·¹´½200mcg, ¾Æ¿¬50mg VD5000 IU + tumeric400mg  or Quercetin400mg // bromelain 100mg +¾ÈÅä½Ã¾È 170mg + ¾ËÆÄ¸®Æ÷»ê600mg..¹Ù½ºÆ¼³­¿¥¾Ë35mg ¸ÞÆ®Æ÷¸£¹Î500mg 
===================
[[1ÇüIFN Áõ»ê+ SIRT1Ȱ¼º+nrf2Ȱ¼º((Ç×¾Ï-Ç׳ëÈ­-Ç׿°-ÇнÀ/±â¾ïÁõÁø-Ȱ·ÂÁõÁø +¹ÙÀÌ·¯½º°¨¿° ¿¹¹æ ¹× ¹Ú¸ê))]]=10+9.....Æ®¸®¸ÞŸÁöµò-¸ÞÆ®Æ÷¸£¹Î-¸®Æ÷»ê-¾ÈÅä½Ã¾È-Ÿ³ª¹Î-ºê·Î¸á¸°-¿£Å×·Ð-SAMe-HCQ-VD + VC-B3-Zn-Se-MSM-¾ËÅ׹̽ôÑ-Ŀť¹ÎorÄõ¼¼Æ¾-¾Æ½ºÅ¸»êÄ£/·çÅ×ÀÎ
====respiratory burst : NAD(P)H+2O -->NAD(P)+, 2O2-, H+=======
NADPH ¹× NADH´Â ¸Å¿ì °­·ÂÇÑ ÀüÀÚ°ø¿©Ã¼·Î¼­ ÀλêÈ­ÀüÀÌÈ¿¼Ò³ª oxidase¿¡ ÀÇÇØ »êÈ­ µÇ¾î °¢°¢ NAD+ ³ª NADP+ °¡ µÇ¸é¼­ ÀüÀÚ e-¿Í ¼ö¼ÒÀ̿ H+¸¦ ³»¾îÁÜÀ¸·Î½á ¼¼Æ÷¿¡ ȯ¿ø·ÂÀ» Á¦°øÇϰí ÀÖÀ½( »êÈ­ °á°ú ROS ¹ß»ýµÊ).......¹Ù·Î ÀÌ NAD+¸¦ ±âÁ¦·Î »ç¿ëÇØ¼­ ¾ÈÁ¤µÈ »óÅÂ(¾Æ¼¼Æ¿È­»óÅÂ)¿¡ ÀÖ´Â ±âÁ¦(¿¹ :PGC1alpha)ÀÇ Å»¾Æ¼¼Æ¿È­¸¦ À¯¹ß½ÃÄѼ­ Ȱ¼º»óÅ·Π¸¸µé¾î ÀÛµ¿µÇµµ·Ï ¸¸µå´Â °ÍÀÌ SIRT1ÀÌ ÇÏ´Â ÀÏÀÓ.....ÀÎü´Â ȯ¿ø·Â Á¦°øÀ» À§ÇØ ÁÖ·Î NADH¸¦ »ç¿ëÇϰí ÀÖÀ¸³ª(SIRT1 Ȱ¼ºÁ¦·Î ÀÛµ¿ÇÏ´Â niacinamide(NAM)´Â NAMPT(NAMÀλêÈ­ÀüÀÌÈ¿¼Ò)¸¦ ÀÛµ¿½ÃÄѼ­ NADH·Î ºÎÅÍ NAD+¸¦ Áõ»êÇÏ¿© SIRT1Ȱ¼º±âÁ¦·Î Á¦°øÇϰí ÀÖÀ½)   ....½Ä¹°Àº ±¤ÇÕ¼º¿¡ ȯ¿ø·ÂÀ» Á¦°øÇÔ¿¡ À־ NADPH¸¦ »ç¿ëÇϰí ÀÖ´Â ¹Ù, NADPH¸¦ »êÈ­ÇÏ´Â .NADPH oxidase µé(NOXs) Áß [¹°·Ð NOX1, NOX4 ¾ïÁ¦½Ãų ¶§¿¡µµ ROS¼Ò°Å°¡ È®Àεǰí ÀÖÀ¸¸ç, IFN-alpha, beta,gamma»ý»ê Áõ°¡°¡ µ¿¹ÝÇÑ´Ù°í º¸Áö¸¸] ƯÈ÷ NOX(NOX2)¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϸé(±×°á°ú ROS ¼Ò°Å°¡ ¼ö¹ÝµÊ) 1Çü ÀÎÅÍÆä·Ð(¾ËÆÄ, º£Å¸ IFN)ÀÌ À¯µµµÊÀÌ È®ÀεǾî ÀÖÀ½......Áï, NOX2 inhibitorµéÀº 1Çü ÀÎÅÍÆä·Ð À¯µµÁ¦(IFN-1 inducer)¿ªÇÒÀ» ÇÔ.......[È®Á¤µÈ]´ëÇ¥ÀûÀÎ NOX2 inhibitors´Â trimetazidine, sulforaphan, ºñŸ¹Î B3, ºñŸ¹ÎD, alpha-lipoic acid antocyanine of elderberry, berberine, beta-sitosterol, curcumin, quercetine, ficetine,µîÀÌ ÀÖÀ½ (^À°Á¾¿ëÃßÃâ¹°/beta-sitosterol :SIRT1 activator + nrf2 activator + NOX2inhibior/IFN-1inducer).....Natural Compounds as Modulators of NADPH Oxidases
------------------
ALa/Vast/metf/sily-tana/ente/brom/NAC-SAMe/HCQ [[VD.VB2,B3.Zn.Se.curcu]] 
----------------
***TGF-1beta inhibitor (¼¶À¯È­ ¾ïÁ¦ local/systemic fibrosis, ARDS¾ïÁ¦)...NAC..±Û¸®½Ã¸®Áø, Ŀť¹Î..EGCGµµ µ¿ÀÏÈ¿°ú): TGF1beta-CCN1 TGFβ1 À¯µµ CCN1 ¹× ET-1, α-SMA mRNA ¹ßÇöÀ» ¾ïÁ¦ 
***TLR4 inhibitor( DAMP response ¹× STINGÀå¾Ö¾ïÁ¦ -- sepsis, MODS¾ïÁ¦)..Ŀť¹Î, ¼³Æ÷¶óÆÇ 
**ACTn-tume/brom-MSM/ART-ZnSeD[[SIRT1activator-Nrf2activator--NOX2inhibitionORnot]]The Effect of N-Acetylcysteine on RespiratoryEnzymes, ADP/ATP Ratio, Glutathione Metabolism,and Nitrosative Stress in the Salivary GlandMitochondria of Insulin Resistant Rats
============
@@@ NRF2 activatorÅõ¿©½Ã ±â´ëÇÒ ¼ö ÀÖ´Â ¹Ù, ARE À¯ÀüÀÚÀü»ç ÅëÇÑ nrf2°æ·ÎȰ¼ºÀÇ Á÷Á¢È¿°ú 
[nrf2Ȱ¼ºÀÚ±ØÃËÁø¿ä¼Òµé-»ó·ù] oxidative stress, metabolic stress, oncogenic stress 
**oxidative stress : (³»Àμº)¹ÌÅäÄܵ帮¾Æ »êÈ­ÀλêÈ­°úÁ¤»ê¹°, p450´ë»ç»ê¹°, peroxisome´ë»ç»ê¹°, ¿°Áõ¼¼Æ÷Ȱ¼ºÈ­»ê¹° (¿ÜÀμº)xenobiotics, ¿°¼ÒÈ­ÇÕ¹°, ¹æ»ç¼±, °¨¿°º´¿ø, ¿°Áõ¼º»çÀÌÅäÄ«Àεé..ÀÏÂ÷»ê¹°Àº superoxide anion..
^^SOD(O2-,superoxide anion --> H2O2),==> Catalase/GPx(H2O2--->H2O+O2)
[nrf2°æ·Î Ȱ¼º°á°ú ¼¼Æ÷º¸È£±â´É ¹ßÇö Áõ»ê¹°-ÇÏ·ù]] :::2»ó ÇØµ¶È¿¼Òµé(´ëÇ¥::NQO1, GST, UGT) ¹× Ç×»êÈ­È¿¼ÒµéÀ» »ý»ê. cf>*ÇØµ¶/Á¦µ¶ Á¦1»ó(phase I) :¿ÜºÎÅõ¿©È­ÇÕ¹°(xenobiotic)ÀÌ  CYP1,2,3,4ÀÇ ÀÛ¿ë °ÅÃÄ non-electrophilic ¶Ç´Â reactive electrophiic ´ë»ç¹°(¹ÝÀÀ¼º, ÀüÀÚģȭ¼º´ë»ç¹° ±×´ë·Î´Â µ¶¼º»óÅÂ, À¯ÀüÀÚº¯Çü ¹× ¹ß¾Ï À¯¹ß °¡´É)·Î Àüȯ...±×ÈÄ¿¡ ¼ö¹ÝµÇ´Â ¹«µ¶È­°úÁ¤ÀÌ ÇØµ¶/Á¦µ¶ Á¦2»ó(phase II)
--¾à¹°, µ¶¼ÒµéÀÇ Á¦µ¶/ROSÀÇ Ç×»êÈ­--
**NQO1 :: NAD(P)H quinone oxidoreductase1 : »êÈ­/ȯ¿ø¹ÝÀÀ ¹× »êÈ­½ºÆ®·¹½º¸¦ À¯¹ßÇÏ´Â °íȰ¼ºquinoneÀÇ È¯¿ø/Á¦µ¶ ´ã´ç
**GST :: Glutathione S-transferase : ¼¼Æ÷Áú-¹ÌÅäÄܵ帮¾Æ, ¹ÌÅ©·Î¼Ø¿¡¼­ GSH¿¡ °áÇÕµÈ ³»Àμº/¿ÜÀμºµ¶¼º ´ë»ç¹°ÀÇ ÀüÀÚ ÁßÇÕü¸¦ ºÐÇØ/Á¦µ¶ ´ã´ç
**UGT :: UDP-glucuronosyltransferase  : glucurinidationÅëÇØ Áö¿ë¼ºµ¶¼Ò¸¦ ¼ö¿ë¼ºÀ¸·Î º¯È¯
**thioredoxin (TXN1, PRDX1, TXNRD1, and SRXN1) : °íȰ¼ºperoxide(H2O2 ¹× peroxynitrite)ÀÇÁ¦µ¶À» ´ã´çÇÏ´Â peroxyredoxinÀ» º¸Á¶ÇÏ´Â ¿ªÇÒ
**Glutathione ÇÕ¼ºÈ¿¼Ò (GCLC/GCLMÀº GSH»ý»êÀÇ rate-limiting step, ±× ¿Ü¿¡ GSR, GPX2, and SLC7A11), 
**Mrps ::´ÙÁß¾àÁ¦³»¼º multidrug resistance–associated proteins (ABCC1 and ABCC2), ¼¼Æ÷¸·¼ººÐÀ¸·Î¼­ ´ãÁó-Ç÷Àå³»·Î µ¶¼º´ë»ç»ê¹°µéÀ» ¹èÃâ Á¦°Å 
--¼¼Æ÷ȯ¿ø´ÉÁõ´ë--
**NADPHÀç»ý»ê(G6PD, PGD, ME1, IDH1)ÅëÇÑ ¼¼Æ÷ÀÇ È¯¿ø´É Áõ´ë :  G6PD ¹× PGD´Â Æ÷µµ´çÀÇÁ¸¼ºpentose phosphate pathway È¿¼Òµé, ME1 and IDH1´Â central carbon metabolism°ü·ÃÈ¿¼Òµé  
--iron/heme Ç×»ó¼ºÀ¯Áö--
**Iron´ë»ç(HO-1, ÈѸ®Æ¾ heavy chain/light chain°ü·ÃÀ¯ÀüÀÚ FTL1/FTH1) : iron/heme Ç×»ó¼ºÀ¯Áö, 
^±ÔÄ¢Àû¼¼Æ÷ÀÚ»ìapoptosis°ú´Â À¯ÀüÀû-»ýÈ­ÇÐÀûÀ¸·Î ºÐ¸íÈ÷ ´Ù¸¥ ¼¼Æ÷ÀÚ¸êÇÁ·Î±×·¥À¸·Î¼­ ¼¼Æ÷³» °ú»êÈ­ÁöÁú°ú öºÐÃàÀûÀ¸·Î ¾ß±âµÇ´Â öºÐÀÇÁ¸¼º ¼¼Æ÷»ç¸êÀÎ ferroptosis(±× °á°ú, ¾Ï-½Å°æÅðÇàÁúȯ-½ÉÇ÷°üÁúȯ À¯¹ß), À̰ÍÀ» Â÷´Ü 
^HO-1..hemeÀ» ºÐÇØÇÏ¿© Ç×»êÈ­¹°Áú biliverdin, Ç׿°¹°ÁúÀÎ Fe++¿Í CO(NFkB¾ïÁ¦)·Î ºÐÇØµÇ¾î, ¼¼±Õ/¹ÙÀÌ·¯½ºÀÇ Áõ½ÄÀÇ ´Ü°èº° Â÷´Ü ÅëÇØ sepsis ¹ß»ý ¾ïÁ¦, °íÇ÷¾Ð-µ¿¸Æ°æÈ­-±Þ¼ºÆó/½ÅÀå¼Õ»ó, °ÝÅë ¹ß»ý ¹× ¾ÇÈ­¸¦ Â÷´Ü.
=====[[¾Ï¿¹¹æ ¹× Ä¡·á +COVID19¿¹¹æ : õ¿¬¹°...À̵éÀº SIRT1Ȱ¼ºÁ¦µé]]====
**mTOR´Â ¼¼Æ÷³»´Ü¹éÁúÁõ»ê-¼¼Æ÷¼ºÀå°úÁ¤À» ÀÚ±Ø(¼¼Æ÷ºÐ¿­°¡´ÉȽ¼ö´Â ¼¼Æ÷¸¶´Ù ±× ÇѰ谡 ÀÖ°í ±× ÇѰ踦 ³Ñ¾î¼­¸é ¼¼Æ÷ÀÚ»ìÀÌ ÀϾ!!)//¿ÜºÎ½ºÆ®·¹½ºÀڱصéÀº °á±¹ mTOR¸¦ ¾ïÁ¦ÇÏ¿© ¼¼Æ÷Áõ½Ä¾ïÁ¦=»ýü¼ö¸í¿¬ÀåÀ» ²ÒÇÔ... SIRT1Ȱ¼ºÁ¦µéÀº SIRT1Ȱ¼ºÀÚ±Ø -->(mTOR¸¦ ¾ïÁ¦Á¶ÀýÇÏ´Â) Tuberin= TuberousSclerosisComplex2(TSC2)¸¦ Ȱ¼ºÀÚ±Ø==>mTOR¸¦ ¾ïÁ¦Á¶Àý :: ¼ö¸í¿¬Àå-Ç׳ëÈ­¹ÝÀÀ À¯µµ
** PI3K/Akt/mTOR °æ·ÎÀÇ Á¶ÀýÀå¾Ö°¡ Ư¡ÀÎ ¾Ï¼¼Æ÷´Â Á¤»ó¼¼Æ÷¿Í ºñ±³ÇØ º¼ ¶§ PI3K/Akt/mTOR ¾ïÁ¦Á¦¿¡ ´õ ¿¹¹ÎÇÏ°Ô ¹ÝÀÀÇÔÀ¸·Î½á ¾Ï¿¹¹æ ¹× ÁøÇ༺ ¾ÏÄ¡·á¿¡ µµ¿òµÊ 
::: ÀÌ¿¡ ÇØ´çµÇ´Â õ¿¬ºÒÁú·Î¼­´Â Ŀť¹Î[°­È²]--DIM[ºê·ÎÄݸ®/Äݸ®Çöó¿ö]--EGCG/Ä«ÆäÀÎ[³ìÂ÷/Ä¿ÇÇ]--VE, Äõ¼¼Æ¾[¾çÆÄ/Â÷/Æ÷µµ/»ç°ú]--ÇǼ¼Æ¾[µþ±â/»ç°ú/°¨/¾çÆÄ], ¾ÆÇǰԴÑ[»ç°ú/¿À·»Áö/ü¸®/Æ÷µµ], ·¹½ºº£¶óÆ®·Ñ[ÀûÆ÷µµ/ÀûÆ÷µµÁÖ]--¼¿¶ó½ºÆ®·Ñ, À̼ÒÇöóº», Å©¸³Åäź½Ã³í........ÇÑÆí, .COVID19¿¹¹æÈ¿°ú°¡ ÀÔÁõµÈ ½Ä¹°·Î¼­´Â  :: »ý°­/½ÉȲ/¸¶´Ã/¾çÆÄ/°èÇÇ/·¹¸ó/´Ô/¹ÙÁú/¾à¿ë¹ö¼¸/ÆÄÆÄ¾ßÀÙ  ((ºñŸ¹ÎD°¡ Æ÷ÇÔµÊ))
@Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
@Natural products as home‐based prophylactic and symptom management agents in the setting of COVID‐19
@Phytochemicals and PI3K Inhibitors in Cancer—An Insight
:::: PI3K/AKT/mTOR, NF-kB, autophagy, MEK-ERK, inflammation, oxidative stress and apoptosis.
@All About mTOR + Natural mTOR Inhibitors & Activators
@Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
===´º·ÎÇʸ°-1Àº VEGF-A¿Í °øÅë¼ö¿ëü·Î ÀÛµ¿µÊ==
^^^NRP1¿¡ ´ëÇÑ VEGF °áÇÕÀº ³»ÇÇ ¼¼Æ÷ À̵¿ÀÇ VEGF ÀÚ±Ø, NRP1°ú VEGFR2 °£ÀÇ º¹ÇÕü Çü¼º ¹× FAK Tyr407 ÀλêÈ­¸¦ ÅëÇÑ ½ÅÈ£ Àü´Þ¿¡ ÇʼöÀû.....³»ÇÇ ¼¼Æ÷¿¡¼­ ´º·Î Çʸ° -1 (NRP1)Àº Ç÷°ü ³»ÇÇ ¼ºÀå ÀÎÀÚ (VEGF) -A¿¡ °áÇÕÇϰí KDR°ú °áÇÕÇϰí VEGF ½ÅÈ£¸¦ °­È­ÇÏ¿© Ű³ªÁ¦ »ðÀÔ µµ¸ÞÀÎ ÇÔÀ¯ ¼ö¿ëü (KDR)¿¡ ´ëÇÑ ÄÚ¾î ¼ö¿ëü ¿ªÇÒÀ»ÇÏ´Â °Í...VEGF ¶Ç´Â VEGF-A´Â Ç÷°ü »ý¼º ¹× Ç÷°ü »ý¼ºÀ» ÀÚ±ØÇÏ´Â Ç÷°ü ³»ÇÇ ¼¼Æ÷¿¡ ´ëÇÑ Æ¯Á¤ À¯»ç ºÐ¿­Ã¼ÀÓ
...VEGF´Â Ƽ·Î½Å Ű³ªÁ¦ ¼ö¿ëü, VEGFR1 ¹× VEGFR2 (Ű³ªÁ¦ »ðÀÔ µµ¸ÞÀÎ ÇÔÀ¯ ¼ö¿ëü, KDR)¸¦ ÅëÇØ ÀÛ¿ë. ƯÈ÷, KDRÀº »ýÁ¸, Áõ½Ä, À̵¿, Ç÷°ü Åõ°ú¼º, ¼¼´¢°ü »ý¼º, NO ¹× ÇÁ·Î ½ºÅ¸³ëÀÌµå »ýÇÕ¼º, À¯ÀüÀÚ ¹ßÇöÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ »ý¸®Àû ±â´ÉÀ» °¡Áø ¿©·¯ °¡Áö ´Ù¸¥ ½ÅÈ£ Àü´Þ ij½ºÄÉÀ̵带 Ȱ¼ºÈ­ÇÏ¿© ³»ÇÇ ¼¼Æ÷¿¡¼­ VEGF ½ÅÈ£ Àü´ÞÀ» ¸Å°³ÇÏ´Â µ¥ Áß¿ä
...KDR¿¡ °áÇÕÇÏ´Â VEGF´Â Æ÷½ºÆÄƼµô À̳ë½ÃÅç 3- Ű³ªÁ¦ ¹× ¼¼Æ÷ »ýÁ¸À» ´ã´çÇÏ´Â ÁÖ¿ä °æ·Î ÀÎ Akt / ´Ü¹éÁú Ű³ªÁ¦ B¸¦ Ȱ¼ºÈ­  ¼öÇà.
.. ¶ÇÇÑ VEGF´Â Æ÷½º Æ÷ ¸®ÆÄÁ¦ CγÀÇ °­·ÂÇÑ È°¼ºÈ­ Á¦·Î¼­ ¼¼Æ÷ ¿Ü ½ÅÈ£ Á¶Àý Ű³ªÁ¦ -1 ¹× -2 (ERK1 ¹× ERK2), ´Ü¹éÁú Ű³ªÁ¦ C ¹× ´Ü¹éÁú Ű³ªÁ¦ D °æ·ÎÀÇ È°¼ºÈ­¸¦ ¸Å°³... ÀÌ È°¼ºÈ­´Â Áõ°¡ µÈ À¯ÀüÀÚ ¹ßÇö, À¯»ç ºÐ¿­ , ¼¼Æ÷ À̵¿ ¹× ÇÁ·Î ½ºÅ¸ »çÀÌŬ¸° »ý»êÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡..
 . ³»ÇÇ ¼¼Æ÷¿¡¼­ VEGF ½ÅÈ£ Àü´ÞÀÇ ¶Ç ´Ù¸¥ Áß¿äÇÑ ¸Å°³Ã¼´Â ¼¼Æ÷ ¿îµ¿ ¼º°ú ¾×ƾ ¼¼Æ÷ °ñ°Ý Á¶Á÷¿¡ Áß¿äÇÑ ¿ªÇÒÀ»ÇÏ´Â Src / ÃÊÁ¡ Á¢Âø Ű³ªÁ¦ (FAK) °æ·ÎÀÓ....   KDRÀº ³»ÇÇ ¼¼Æ÷¿¡¼­ ÀÌ·¯ÇÑ ¸ðµç VEGF È¿°ú¿¡ Áß¿äÇÏÁö¸¸ NRP1Àº ƯÈ÷ ¼¼Æ÷ ¿îµ¿ ¼º°ú È­ÇÐ ÁÖ¼º À̵¿¿¡ Áß¿äÇÏÁö¸¸ ¼¼Æ÷ ºÐ¿­¿¡´Â °ÅÀÇ ¿µÇâÀ» ¹ÌÄ¡Áö ¾ÊÀ½. 

[[COVID19ÀÇ ¶Ç´Ù¸¥ ħ½À°æ·Î...Ä¡·áŸ°Ù ]] COVID19´Â º¸Åë ¼¼Æ÷¸·Ç¥¸éÀÇ ACE2¼ö¿ëü¸¦ ÅëÇØ ¼÷ÁÖ¼¼Æ÷ÀÇ Ä§½ÀÀ» ÀÏÀ¸Å°Áö¸¸ ½Å°æ ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀº spike protein S1ÀÌ ¼¼Æ÷¸·Ç¥¸é¿¡ °áÇյǾî ÀÖ´Â tyrosine kinase receptor·Î¼­ °ø¿ë¼ö¿ëüÀÎ, neuropilin-1/VEGF-A¸¦ ³¬¾ÆÃ¤¾î °áÇÕÇØ¼­ pro-pain signaling systemÀ» Â÷´ÜÇÏ°í ½Å°æ¼¼Æ÷³»·Î ħ½À À¯¹ß(Á¶Á÷À̳ª ±â°üħ½À¼Õ»ó½Ã ±×°ÍÀ»  ÀÚ°¢ÇÏ°Ô ÇÏ´Â ½ÅÈ£ÀÎ Åë°¢À» Â÷´Ü/ħ¹¬ÄÉ ÇÔ) ==>¹«Áõ»ó°¨¿°ÀÚ¸¦ ÅëÇÑ ¹ÙÀÌ·¯½ºÀüÆÄÈ®»ê À¯¹ß +Áø´Ü½Ã ÀÌ¹Ì Á¶Á÷À̳ª ±â°üµéÀÇ ¼Õ»óÀÌ ÁøÇàµÇ¾î ÀÖ´Â »óŰ¡ µÊ [°ñ°üÀý¿° ÅëÁõÀÌ ½ÉÇÒ¼ö·Ï VEGF-A/neuropilin geneÀÇ È°¼ºµµ°¡ ³ô¾Æ¼­ Ç÷û VEGF-A°¡ Áõ°¡ÇßÀ½!!]...anti-neuropilin-1 = anti-VEGF-A = mTOR inhibitor
=====
 ## PI3K/Akt/mTOR °æ·ÎȰ¼ºÀº ¼¼Æ÷ÀÚ»ì/³ëÈ­ ¹× ¾Ï¼¼Æ÷Áõ½Ä-À̵¿-ºÐÈ­ ¹× Ç×¾ÏÁ¦³»¼ºÀÇ ¹ßÇö °ü·ÃµÊ : = PI3K/Akt/mTOR Â÷´ÜÁ¦µéÀº ´ë°³ SIRT1Ȱ¼ºÈ¿°ú¸¦ ³ªÅ¸³»¸ç ±×¿Ü¿¡µµ ACE2¿Ü¿¡ COVID19ħ½À°æ·Î·Î¹àÇôÁø VEGF-A/neuropilin-1(NRP-1) °æ·Î ¾ïÁ¦Á¦ È¿°ú¸¦ ÇÔ²² ³ªÅ¸³¿À¸·Î½á °á±¹ COVID19 ħ½ÀÂ÷´Ü + ½Å°æÀμºÅëÁõ ¹× ¾Ï¼ºÅëÁõ Â÷´Ü + ¾ÏÁٱ⼼Æ÷Áõ½Ä ¹× ºÐÈ­, À̵¿, ¼ºÀåÀ» ¾ïÁ¦+ Ç×¾ÏÁ¦¹Î°¨µµ Áõ°¡/¾àÁ¦³»¼º¹ß»ýȸÇÇ È¿°ú¸¦ ¾òÀ» ¼ö ÀÖÀ½ ((PI3K/Akt/mTOR inhibitors : Ä¿Å¥¹Î. ½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG,ÆÄÀÌÆä¸°, Äõ¼¼Æ¾, È£³ëŰ¿Ã, ·¹½ºº£¶óÆ®·Ñ))...
##**¾Æ¸£Å׹̽ôÑ(mTOR°æ·Î ¾ïÁ¦+VEGF¾ïÁ¦+ACE2¾ïÁ¦=COVID19ħ½ÀÂ÷´Ü+Ç×¾ÏÀÛ¿ë+Ç×±ÕG+ÀÛ¿ë/Ç×Áø±Õ) --³»ÇÇ ¼¼Æ÷¿¡¼­ VEGF, NF-kB, VEGF-Flt-1, KDR/Flk-1 ¼ö¿ëüÀÇ ¹ßÇö ¼öÁØÀ» °¨¼Ò ½ÃÄÑ Ç×¾Ï È°¼ºÀ» ÃËÁø. **Artesunate -- artemisininÀÇ ¹ÝÇÕ¼º À¯µµÃ¼. HUVEC¿¡¼­ ¿ë·® ÀÇÁ¸ÀûÀ¸·Î Ç÷°ü ½Å»ýÀ» ¾ïÁ¦ÇÏ¿© ¾Ï ¹ß»ýÀ» ¿¹¹æ. TGF-β1°ú IL-10ÀÇ ¼öÄ¡¸¦ °¨¼Ò½ÃÄÑ ¸é¿ª ¾ïÁ¦¸¦ °¨¼Ò½ÃŰ°í ¾Ï°ú ½Î¿ì´Â Ç×¾Ï ¸é¿ªÀ» Á¦°ø. (Áß¿äÇÑ Ç×¾ÏÁ¦ ÀÏ °¡´É¼º)...HCQµµ µ¿ÀÏÇѱâÀüÀ¸·Î Ç×¾ÏÁ¦ ±â´É º¸À¯.
##Diseases Associated With mTOR Activation
Aging [15].....Cancer [16, 17]........Autoimmune disease.......Depression [18]......Diabetes [9]....Obesity [9].....Alzheimer’s [9]......Macular degeneration [9]....Kidney disease [9]....Epilepsy [9]...Autism (9, 19)....Chronic pain [9]....SLE [20]
##Inhibitors of mTOR
[mTOR pathway Â÷´Ü±âÀüÀÇ ¸é¿ª¾ïÁ¦Á¦µé] transplant rejection¾ïÁ¦/anticancer therapy. 
Tacrolimus (Prograf, Advagraf)....Sirolimus (Rapamune)....Temsirolimus (Torisel)...Everolimus (Afinitor, Zortress)
The following strategies also inhibited the mTOR pathway, but the studies were mostly done in cells. Consult your doctor before implementing them and never used them to replace approved therapies.
[mTOR°æ·Î Â÷´Ü À¯¹ß=mTOR inhibitors]
^^Protein restriction [21, 22]...Calorie restriction [23]...Ketogenic Diets [24].....Intermittent Calorie Restriction [23].....Exercise (inhibits mTOR in the liver and fat cells, but activates it in the brain, muscle, and heart) [25, 26]....
^^remedy : Cortisol/Glucocorticoids [5]....Metformin [27]....NAC [28]....Resveratrol [29]....Aspirin [30]....Omega-3 [31]....Extra Virgin Olive Oil [32]....EGCG/Tea [33, 1, 34]....Curcumin [35, 1, 36].....R-Lipoic Acid [37]....Caffeine [38, 39, 1]....Fisetin (in fat cells) [40]....Apigenin [41].....Quercetin [42]....Genistein [1]....DIM [1]....Ursolic acid [43]....Alcohol [44]....Emodin (found in Fo-Ti, Rhubarb, Aloe) [45]....Andrographis/Andrographolide [46]....Pomegranate/Ellagic acid [47]....Reishi [48]....Milk thistle/Silymarin [49]....Oleanolic acid [50]...Anthocyanins/Grape Seed Extract [51]....Astragalus [52]....Rhodiola [53]....Carnosine [54]....Plumbagin(black walnut hull) [55]....Glucagon [56]....AICAR [27]
==========
[[PI3K-Akt-mTOR inhibitors, natural products]] **dec.neuropathic Pain via NRP-1 block
Name of compounds --Chemical classification::: Therapeutic uses
1>Gingerols --Predominated phenols of ginger oil  :: Anticancer, antineuroinflammatory, antioxidant, anti-inflammatory, anti-cancer
2>**Curcumin --Flavonoid ::: Cardiovascular diseases, arthritis and inflammation, breast, gastric, colon, prostate cancers, melanoma, lymphoma, and leukemia
3>Diallyl Trisulfide --Organosulfur compound ::: Diabetes, cardiovascular disease, stimulate immune system, induce apoptosis in colon, gastric, prostate, and breast cancers
4>Emodin --Anthraquinone derivative ::: Several human cancers, neuroprotective, anti-viral
5>Ginsenoside RG3---Steroid glycosides and triterpene saponins ::: Numerous types of cancers- ovarian, lung, melanoma
6>D-Rhamnose β-hederin --Triterpenoid saponin :: :Cardiovascular disease, neuroprotective, antioxidant, anti-proliferative, neurodegenerative disease
7>Honokiol ---Neolignan biphenols :::Anti-thrombotic, anti-inflammatory, anti-oxidant, anti-cancer- multiple myeloma, lung, and colorectal
8>Matrine --Tetracyclic alkaloid ::: Anti-cancer, anti-inflammatory, anti-viral, anti-fibrotic, anti-arrhythmic, immunosuppressive
9>Parthenolide---Sesquiterpene lactone ::: Arthritis, fever, head ache, anticancer- prostate, skin, breast, bile duct, bowel, pancreas
10>Plumbagin---Naphthoquinone :::Anti-inflammatory, neuroprotective, hypolipidemic, anticancer, anti-atherosclerotic, anti-fungal, antibacterial
11>Triptolide---Diterpenoid triepoxide :::Arthritis, variety of cancers, anti-inflammatory, immunosuppressive, anti-cystogenesis
12>Wogonin---Flavone :::Anti-bacterial, antiviral, anti-oxidant, anti-inflammatory, anti-cancer
13>Thymoquinone --Benzoquinone of essential oil ::: Bronchial headache, asthma, dysentery, gastrointestinal problems
14>Andrographolide --Labdane diterpenoid ::: Upper respiratory tract infections, immunomodulatory, anti-cancer
15>**Resveratrol --Natural polyphenol with stilbene:::Anti-viral, anti-inflammatory, anti-leukemic, neuroprotective, chemoprotective, anti-oxidant
16>**Epigallocatechin-3-gallate --Polyphenol, catechin, ester of epigallocatechin and gallic acid :::Cardiovascular disease, anti-cancer, anti-obesity, skin protection from ionizing radiation
17>**Quercetin --Flavonoid:::Hay fever, diabetes, peptic ulcer, cataracts, asthma, schizophrenia, gout inflammation, viral infections, anti-cancer
18>Fistein --Flavonoid :::Anti-oxidant, anti-inflammatory, anti-cancer
19>Luteolin  --Flavonoid ::: Anti-cancer, anti-oxidant, anti-inflammatory
20>Apigenin --Flavonoid ::: Anti-inflammatory, sedative, numerous cancers- prostate, melanoma, colon, and breast
21>**Indole-3-carbinol --Breakdown product of glucosinolate ::: Numerous cancer types- breast, colon, thyroid, gastric, prostate and mesothelioma
22>**Di-indolylmethane --Derived product from digestion of indole-3-carbinol ::: Anti-cancer
23>**Sulforaphane --Organosulfur compound with isothiocyanate group ::: Anti-cancer and anti-viral
24>Phenethyl isothiocyanate --Isothiocyanate derivative ::: Numerous cancers
25>Benzyl isothiocyanate --Isothiocyanate derivative ::: Anti-cancer
26>Dehydroglyasperin D --Prenyl flavonoid  ::: Anti-obesity, aldose reductase inhibition, anti-cancer, anti-oxidant
27>Evodiamine --Quinolone alkaloid ::: Anti-nociceptive, anti-anoxia and vasorelaxant
28>Piceatannol --Natural analog of Resveratrol ::: Anti-cancer, anti-inflammatory, atherosclerosis, hypercholesterolemia, angiogenesis
29>Ellagic acid --Polyphenol ::: Anti-bacterial, anti-viral, anti-cancer
30>**Berberine via inhibition of ERK/mTOR signalling pathway ::: NAFLD
#CQ/HCQ artemisinin.artesunate == ACE2 inhibitor+VEGF inhibitor(Ç×¹ÙÀÌ·¯½º), autophagy inhibitor(Ç׳ëÈ­),,anticancer effect(¾ÏÇ÷°ü½Å»ý¾ïÁ¦)#
#[[ºê·Î¸á¶óÀÎ COVIDF19¿¡¼­ÀÇ ÀÛ¿ë±âÀü]] ¼÷ÁÖ¼¼Æ÷ ¼¼Æ÷¸·ÀÇ ACE2 ¹× TMPRSS2ÀÇ ¹ßÇöÀ» ¾ïÁ¦, VEGF-A/neuropilin-1 ¾ïÁ¦, COVID19 ½ºÆÄÀÌÅ© ´Ü¹é Àý´Ü/ºÐÇØ ==>COVID19 °¨¿°/¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½À ¾ïÁ¦(G+/G-Ç×±ÕÁ¦+Ç×¹ÙÀÌ·¯½ºÁ¦·Î ºÐ·ùµÊ) + Ç×¾ÏÁ¦(¾ÏÇ÷°ü½Å»ý¾ïÁ¦+¾Ï¼¼Æ÷ÀÚ¸êÀ¯µµ +NK¼¼Æ÷Áõ»ê) +Äݶó°Õ»ý»êÁõ°¡/ÁÖ¸§¹ß»ý¾ïÁ¦Á¦·Î¼­ »ç¿ë °¡´É....COVID19´Â SARS-CoV-2 µ¿Á¾ »ï ÇÕü ¹ÙÀÌ·¯½º·Î¼­  ½ºÆÄÀÌÅ© ´Ü¹éÁú (S1)Àº Ãʱâ ÁøÀÔÀ» À§ÇØ ¼÷ÁÖ ¼¼Æ÷ÀÇ ¼ö¿ëü ACE-2¿¡ °áÇÕÇÑ ´ÙÀ½¿¡´Â S2 ¸Å°³ ¹ÙÀÌ·¯½º-¼÷ÁÖ¼¼Æ÷°£ ¸· À¶ÇÕ ( 4 , 5 )À¸·Î À̾îÁü.. ÀÌ ¶§ S- ´Ü¹éÁúÀº ¼÷ÁÖ ¼¼Æ÷ Ç¥¸é¿¡ ¹ßÇöµÇ´Â TMPRSS2¿¡ ÀÇÇØ ´Ü¹éÁú ºÐÇØ ÇÁ¶óÀ̹ÖÀ» °ÅÄ¡°Ô µÇ´Âµ¥ ( 6 ). TMPRSS2´Â ¼¼¸° ÇÁ·ÎÅ×¾ÆÁ¦ Ȱ¼ºÀ» °®´Â 70kDa À¯Çü II ¸· Ⱦ´Ü ´ç ´Ü¹éÁúÀÌ¸ç  ¸¹Àº Á¶Á÷¼¼Æ÷µé¿¡¼­ ¹ßÇöµÊ ( 7 )..... TMPRSS2´Â 9 °³ÀÇ ¾ÈÁ¤È­ ÀÌȲȭ °áÇÕ°ú 2 °³ÀÇ N- ±Û¸® Ä­ ºÎÀ§¸¦ °¡Áú °ÍÀ¸·Î ¿¹»óµÊ (UniProtKB-O15393)..... ¹Ù·Î ÀÌ ¼÷ÁÖ¼¼Æ÷ ¼¼Æ÷¸·ÀÇ TMPRSS2 ÇÁ¶óÀÌ¹Ö È°¼ºÀº ÀÎÇ÷翣ÀÚ A ¹ÙÀÌ·¯½º ( 8 , 9 ), SARS-CoV ( 10 ) ¹× SARS-CoV-2 ( 6 )¸¦ Æ÷ÇÔÇÑ ¸¹Àº ¹ÙÀÌ·¯½º °¨¿° ¾ïÁ¦¿¡ ÇʼöÀû ¿ä¼Ò°¡ µÊ.). ...BromelainÀº bFGF(¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ), VEGF(Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ), angiopoetin-1 ¹× 2, COX-2, MMP-9, AP-1 ¹× NF-κB¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ç÷°ü ½Å»ý ¼ºÀå ÀÎÀÚ, È¿¼Ò ¹× Àü»ç ÀÎÀÚ¸¦ ¾ïÁ¦Á¶ÀýÇÏ¿© ¾Ï¼¼Æ÷ÀÚ»ìÀ¯µµ(mTORÁõ°¡´Â ¾Ï¼¼Æ÷ ÀÚ»ì, ¾Ï¼¼Æ÷È­Çϰí Àִ¼¼Æ÷µéÀÇ Á¤»ó¼¼Æ÷·ÎÀÇ º¹±Í¸¦ À¯µµ!!...¸á¶óÅä´Ñµµ µ¿ÀÏÇÑ ±âÀü.)[ƯÈ÷ Ç÷°ü½Å»ýÀÇ ÁÖ¿äÇ¥ÁöÀÚ´Â VEGF¿Í COX2!! ]...[AP-1/NFkB(ampk)-MMP9 °æ·Î´Â Á¾¾çħ½À°ü·Ã °æ·ÎÀÓ], Á¾¾çÁõ½ÄÀº Ç÷¼ÒÆÇÀÀÁýÁ¶°Ç¿¡¼­ ÀϾ´Âµ¥...ºê·Î¸á¶óÀÎÅõ¿©½Ã Á¤»óÀÎÀÇ °æ¿ì, Ç÷¼ÒÆÇÀÌ ¾à°£ ÀúÇϵǴ ¼Ò°ßµµ º¼ ¼ö ÀÖÀ½
--------
[Ç×Áø±ÕÁ¦·Î¼­ÀÇ phytochemicals  : Áø±Õ =¹«Á»±Õ,  Ä­µð´Ù,  Å©¸³ÅäÄÚÄí½º] ¾ÈÅä½Ã¾È º£¸£º£¸°/ ºê·Î¸á¸° EGCG ½Ç¸®¸¶¸° ¼³Æ÷¶óÆÇ Ŀť¹Î Äõ¼¼Æ¾ ÆÄÀÌÆä¸° ÇÁ·ÎÆú¸®½º/¸¶´Ã .....
[Ç×Áø±Õ, Ç×±ÕÁ¦·Î¼­ÀÇ A.annua, AZT]..ART¿Í A.annua´Â C. albicans ¹× Å©¸³ÅäÄÚÄí½º, G+±Õ, G-Áß Salmo¿¡´Â ¸ðµÎ Ç×±ÕÀÛ¿ë º¸ÀÓ, ART¿¡ ¾Èµè´Â E.coli¿¡µµ A.annua´Â È¿°ú
==µÎ°³Ãµ°ñ¿ä¹ý, CRANIOSACRAL THERAPY.====
@@BNT162b2 mRNA Covid-19 ¹é½ÅÀÇ ¾ÈÀü¼º ¹× È¿´É NEJM2020-12.
ÃÑ43448¸í(À§¾àF21733.¹é½ÅV21720) -->RT-PCR(+)À¯Áõ»óÀÚ168(F162, V6) : 95%protection.....RT-PCR°Ë»ç sample size(0.38%) ½Å·Úµµ ¹®Á¦ .....¹ÙÀÌ·¯½ºÀ¯ÀüÀÚ·Î ¸¸µå´Â »ý¹é½Å=¹ÙÀÌ·¯½º ±× ÀÚüÀ̱⿡ ¾ß±âµÇ´Â »ç¸Á¿øÀÎÀÎ CSS-DIC ÇÕº´Áõ ¹ß»ýµÇ´Â ¹®Á¦......normalFlora°ø»ý/ħ½ÀºÎÀ§´Â Á¡¸·Àε¥, »ï°¢±Ù³» Á¢Á¾À¸·Î ÀÎÇÑ ¹«¹æºñ»óÅ·ΠÇ÷°ü³»·Î ÁøÀÔ½ÃÄѹö¸®´Â ¹Ù Á¢Á¾·çÆ®ÀÇ ¹®Á¦
=======

===È÷µå·Ï½ÃŬ·Î·ÎÄý Äڷγª19 »ç¸Á°¨¼ÒÁ¶±â Åõ¿©, ¸é¹Ð ½ÉÀå ¸ð´ÏÅ͸µ »ç¸Á·ü À§Çèºñ 66% °¨¼Ò ===[ÀÇÇнŹ®·Àϰ£º¸»ç=±èÀÚ¿¬ ±âÀÚ...2020.07.06] 

ÃÖ±Ù ¼¼°èÀûÀ¸·Î Äڷγª19¿¡ È÷µå·Ï½ÃŬ·Î·ÎÄýÀÇ ÀÓ»ó½ÃÇèÀÌ Áߴܵǰí ÀÖ´Â °¡¿îµ¥, È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ ½ÉÀå °ü·Ã ºÎÀÛ¿ë ¾øÀÌ Äڷγª19 ÀÔ¿ø ȯÀÚÀÇ »ç¸ÁÀ» »ó´çÈ÷ °¨¼Ò½Ãų ¼ö ÀÖ´Ù´Â ¿¬±¸ °á°ú°¡ ³ª¿Ô´Ù.

¹Ì±¹ Ç Æ÷µå Çコ ½Ã½ºÅÛ ¿¬±¸ÁøÀº ´ë±Ô¸ð ȸ°íÀû ºÐ¼® ¿¬±¸ °á°ú À̰°ÀÌ ³ªÅ¸³µ´Ù°í ±¹Á¦ °¨¿°Áúȯ Àú³ÎÀ» ÅëÇØ ¹ßÇ¥Çß´Ù.

±×µ¿¾È È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ È¿°ú¸¦ º¸ÀÌÁö ¸øÇÑ ±âÁ¸ ¿¬±¸¿Í Â÷ÀÌÁ¡À¸·Î ¿¬±¸ÁøÀº Á¶±â¿¡ Ä¡·á¸¦ ½ÃÀÛÇß°í ¸é¹ÐÈ÷ ½ÉÀåÀ» ¸ð´ÏÅ͸µÇßÀ¸¸ç ´Ù¸¥ ¿¬±¸¿Í ¿ë·®¿¡ Â÷À̵µ ÀÖ´Ù°í ¼³¸íÇß´Ù.

À̹ø ¿¬±¸´Â Áö³­ 3¿ù 10ÀϺÎÅÍ 5¿ù 2ÀÏ »çÀÌ Ç Æ÷µå Çコ ½Ã½ºÅÛ¿¡ ÀÔ¿øÇÑ È®ÁøÀÚ ÃÑ 2541¸íÀ» ´ë»óÀ¸·Î Áß°£ 28.5ÀÏ µ¿¾È ÃßÀûµÆÀ¸¸ç ȯÀÚÀÇ Æò±Õ ¿¬·ÉÀº 64¼¼¿´°í 56%°¡ ÈæÀÎÀ̾ú´Ù.

¿¬±¸¿¡¼­ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á ȯÀÚµéÀÇ 82%°¡ ÀÔ¿ø 24½Ã°£ À̳», 91%°¡ 48½Ã°£ À̳» È÷µå·Ï½ÃŬ·Î·ÎÄýÀ» Åõ¿©¹Þ¾Ò´Ù.

È÷µå·Ï½ÃŬ·Î·ÎÄýÀÇ ¿ë·®Àº 1Àϰ ÇÏ·ç 2ȸ 400mg µÎ º¹¿å·®À¸·Î, 2~5Àϰ ÇÏ·ç 2ȸ 200mgÀ» Åõ¿©Çß´Ù.

¿¬±¸ÁøÀÌ È¯ÀÚµéÀÇ ½ÉÀå »óŸ¦ ÀÏÁ¤ÇÏ°Ô ¸ð´ÏÅ͸µÇÑ ¸¸Å­ ´©±¸µµ ÁßÁõ ½ÉÀå ºÎÀÛ¿ëÀ» °ÞÁö ¾Ê¾Ò´Ù.

ƯÈ÷ ½ÉÀå À§Çè ¿äÀÎÀÌ ÀûÀº ÁßÁõ ȯÀÚÀÇ °æ¿ì¿£ È÷µå·Ï½ÃŬ·Î·ÎÄý°ú ¾ÆÁö½º·Î¸¶À̽ÅÀ» º´¿ëÅõ¿©Çß´Ù. º´¿ëÇÑ ¾ÆÁö½º·Î¸¶À̽ÅÀº 1Àϰ ÇÏ·ç 1ȸ 500mgºÎÅÍ ½ÃÀÛÇØ ´ÙÀ½ 4ÀÏ µ¿¾È ÇÏ·ç 1ȸ 250mgÀ» ÁÖ¾ú´Ù.

±× °á°ú ÀüüÀûÀ¸·Î ¿ø³» »ç¸Á·üÀº 18.1%·Î ³ªÅ¸³­ °¡¿îµ¥ Ä¡·áº° »ç¸Á·üÀº È÷µå·Ï½ÃŬ·Î·ÎÄý ´Üµ¶ Ä¡·á ȯÀÚ Áß 13.5%, È÷µå·Ï½ÃŬ·Î·ÎÄý°ú ¾ÆÁö½º·Î¸¶À̽Šº´¿ë ȯÀÚ Áß 20.1%, ¾ÆÁö½º·Î¸¶À̽дܵ¶ Ä¡·á ȯÀÚ Áß 22.4%À¸·Î ³ªÅ¸³µ°í µÎ Ä¡·áÁ¦ Áß ¹«¾ùµµ ¹ÞÁö ¾ÊÀº ȯÀÚ´Â 26.4%·Î ³ª¿Ô´Ù. »ç¸ÁÀÇ 88%´Â È£Èí ºÎÀüÀ¸·Î ÀϾ°í ´ÙÇü ½É½Ç ºó¸ÆÀº ¹ß»ýÇÏÁö ¾Ê¾Ò´Ù.

ÀÌ¿¡ µû¶ó ¿¬±¸ÁøÀº È÷µå·Ï½ÃŬ·Î·ÎÄýÀ̳ª ¾ÆÁö½º·Î¸¶À̽ŠÁß ¾Æ¹«°Íµµ ¹ÞÁö ¾ÊÀº ȯÀÚ¿¡ ºñÇØ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á´Â »ç¸Á·ü À§Çèºñ¸¦ 66% °¨¼Ò½ÃÄ×°í µÎ º´¿ëÀº 71% ÁÙ¿´´Ù°í °á·ÐÁö¾ú´Ù. 

ƯÈ÷ ¿¬±¸ÁøÀº È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ È¿°ú°¡ ÀÖÀ¸·Á¸é ÁßÁõ ¸é¿ª ¹ÝÀÀÀÌ ÀϾ±â ÀÌÀü¿¡ Åõ¿©ÇÒ Çʿ䰡 ÀÖ´Ù°í ÆòÇß´Ù.

´Ü °ü·Ã ³íÆò¿¡¼­´Â È÷µå·Ï½ÃŬ·Î·ÎÄýÀ» ¹ÞÀº ȯÀÚµé °¡¿îµ¥ ½ºÅ×·ÎÀÌµå µ¿½Ã Åõ¿© ȯÀÚ°¡ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº ȯÀÚ¿¡ ºñÇØ 2¹è ÀÌ»óÀ̾ú´Ù¸ç, ÀÌ´Â ÃÖ±Ù ¹ß°ßµÈ µ¦»ç¸ÞŸ¼ÕÀÇ »ç¸Á °¨¼Ò È¿°ú¿Í °ü·Ã ÀÖÀ» ¼ö ÀÖ´Ù´Â ÁöÀûµµ ³ª¿Ô´Ù.((±èÀÚ¿¬ ±âÀÚ  nature@bosa.co.kr))

´ÙÀ½±Û : ¾ÆÅä.Ä¡¸Å.MS.À̸í.ºÒ¾È.±Û·çÅÙ.¾ËÄÝ.³­¼Ò¾Ï
ÀÌÀü±Û : HCQ.PRM3.artemisinin